###################################################################################################################################################################
#Enrichment results using 'Biological Process from Gene Ontology (GO)', created by dcGO Enrichment at 2/06/2016 15:39:53 (day/month/year hour:min:sec)
#Citation: Fang H, Gough J. (2012) dcGO: database of domain-centric ontologies on functions, phenotypes, diseases and more. Nucleic Acids Res (PubMed ID: 23161684)
###################################################################################################################################################################
#
#'GroupID' column: group id (by default 'Group' for single group);
#'GO ID' column: the identifier of ontological terms;
#'GO term' column: the name of ontological terms;
#'xxxx (four levels)' column: term specificity (only appear when using slim version of the ontology; 1 for highly general, 2 for general, 3 for specific, and 4 for highly specific);
#'Z-score' column: Z-score being calculated based on hypergeometric distribution;
#'P-value' column: P-value being calculated based on hypergeometric distribution;
#'FDR' column: FDR used to assess the statistical significance of term enrichments;
#'#Domains (Overlaps|Group|Term|Background)' column: the number of domains, i.e., 'Overlaps' for the number of domains in the input group but also being annotated by the term; 'Group' for the number of domains in the input group (also annotatable by the ontology); 'Term' for the number of domains being annotated by the term; 'Backgroud' for the number of domains that are annotatable by the ontology.
#'Annotated domains' column: a list of semicolon-separated domains in the input group but also being annotated by the term.
#
GroupID	GO ID	GO term	PFAM slim (four levels)	Z-score	P-value	FDR	#Domains (Overlaps|Group|Term|Background)	Annotated domains
Group	GO:0065008	regulation of biological quality	1	13.97	1.05e-34	9.93e-32	125|247|628|3527	PF00001;PF00002;PF00003;PF00010;PF00019;PF00022;PF00024;PF00027;PF00028;PF00041;PF00042;PF00046;PF00048;PF00049;PF00051;PF00057;PF00059;PF00060;PF00061;PF00063;PF00067;PF00068;PF00071;PF00079;PF00084;PF00089;PF00094;PF00100;PF00110;PF00135;PF00147;PF00151;PF00159;PF00167;PF00201;PF00209;PF00210;PF00211;PF00230;PF00246;PF00250;PF00273;PF00292;PF00320;PF00386;PF00435;PF00474;PF00497;PF00503;PF00520;PF00530;PF00560;PF00613;PF00615;PF00622;PF00683;PF00685;PF00688;PF00822;PF00858;PF00868;PF00870;PF00909;PF00927;PF00930;PF00992;PF01007;PF01094;PF01275;PF01347;PF01391;PF01392;PF01404;PF01415;PF01421;PF01431;PF01442;PF01562;PF01576;PF01699;PF01740;PF01813;PF01826;PF01841;PF02024;PF02026;PF02192;PF02210;PF02214;PF02460;PF02736;PF02793;PF02931;PF02932;PF03045;PF03098;PF03299;PF03520;PF04505;PF04553;PF05649;PF05835;PF06459;PF06512;PF07562;PF07645;PF07679;PF07686;PF07710;PF07714;PF07885;PF08344;PF08516;PF08742;PF10409;PF10565;PF10613;PF11527;PF11933;PF12444;PF12756;PF13516;PF13855;PF13895;PF13927
Group	GO:0051239	regulation of multicellular organismal process	1	13.99	2.93e-32	1.38e-29	102|247|448|3527	PF00001;PF00002;PF00003;PF00010;PF00019;PF00024;PF00027;PF00028;PF00031;PF00038;PF00041;PF00046;PF00048;PF00049;PF00051;PF00059;PF00060;PF00061;PF00063;PF00067;PF00068;PF00071;PF00079;PF00084;PF00089;PF00090;PF00100;PF00110;PF00123;PF00125;PF00135;PF00147;PF00167;PF00230;PF00250;PF00292;PF00320;PF00351;PF00386;PF00435;PF00497;PF00503;PF00520;PF00530;PF00560;PF00615;PF00622;PF00688;PF00870;PF00907;PF00992;PF01007;PF01049;PF01085;PF01094;PF01273;PF01391;PF01392;PF01404;PF01415;PF01510;PF01534;PF01562;PF01699;PF01833;PF01979;PF02210;PF02214;PF02460;PF02736;PF02758;PF02793;PF02898;PF02931;PF02932;PF03045;PF03145;PF03299;PF03520;PF03529;PF03736;PF04505;PF05729;PF05835;PF06512;PF06607;PF07562;PF07645;PF07679;PF07686;PF07710;PF07714;PF10409;PF10613;PF11933;PF12444;PF13306;PF13426;PF13516;PF13855;PF13895;PF13927
Group	GO:0007399	nervous system development	1	12.77	5.48e-27	1.73e-24	89|247|397|3527	PF00001;PF00002;PF00010;PF00019;PF00024;PF00028;PF00038;PF00041;PF00046;PF00048;PF00049;PF00053;PF00055;PF00057;PF00060;PF00061;PF00063;PF00071;PF00090;PF00110;PF00123;PF00135;PF00147;PF00157;PF00167;PF00230;PF00246;PF00250;PF00292;PF00320;PF00354;PF00431;PF00435;PF00497;PF00503;PF00520;PF00688;PF00822;PF00870;PF00907;PF00918;PF01049;PF01085;PF01094;PF01153;PF01275;PF01391;PF01392;PF01400;PF01404;PF01410;PF01421;PF01431;PF01442;PF01534;PF01562;PF01576;PF01833;PF01979;PF02210;PF02351;PF02736;PF02793;PF02931;PF02932;PF03145;PF03299;PF03529;PF03736;PF05649;PF05923;PF07645;PF07679;PF07686;PF07710;PF07714;PF08266;PF08344;PF08516;PF10409;PF12003;PF12413;PF12444;PF13306;PF13385;PF13516;PF13855;PF13895;PF13927
Group	GO:0032879	regulation of localization	1	12.61	2.70e-25	6.38e-23	77|247|318|3527	PF00001;PF00002;PF00003;PF00007;PF00019;PF00027;PF00031;PF00040;PF00041;PF00045;PF00046;PF00048;PF00049;PF00055;PF00059;PF00061;PF00063;PF00071;PF00074;PF00084;PF00090;PF00100;PF00110;PF00123;PF00135;PF00147;PF00167;PF00230;PF00250;PF00292;PF00320;PF00386;PF00413;PF00435;PF00503;PF00520;PF00615;PF00622;PF00688;PF00822;PF00907;PF00930;PF01094;PF01391;PF01392;PF01442;PF01471;PF01534;PF01562;PF01833;PF01979;PF02026;PF02210;PF02214;PF02351;PF02460;PF02758;PF02793;PF02898;PF02931;PF02932;PF03299;PF05729;PF06459;PF07645;PF07679;PF07686;PF07714;PF08344;PF10409;PF10613;PF12444;PF13426;PF13516;PF13855;PF13895;PF13927
Group	GO:0023052	signaling	1	11.18	1.09e-23	2.07e-21	111|247|648|3527	PF00001;PF00002;PF00003;PF00007;PF00010;PF00019;PF00027;PF00028;PF00029;PF00038;PF00041;PF00046;PF00048;PF00049;PF00051;PF00057;PF00059;PF00060;PF00061;PF00063;PF00071;PF00079;PF00089;PF00090;PF00100;PF00110;PF00123;PF00129;PF00135;PF00147;PF00157;PF00167;PF00193;PF00209;PF00211;PF00250;PF00292;PF00320;PF00351;PF00386;PF00431;PF00435;PF00474;PF00497;PF00503;PF00520;PF00560;PF00613;PF00615;PF00622;PF00631;PF00683;PF00688;PF00822;PF00870;PF00907;PF00930;PF01007;PF01085;PF01094;PF01153;PF01275;PF01391;PF01392;PF01404;PF01421;PF01534;PF01562;PF01833;PF02192;PF02210;PF02214;PF02351;PF02460;PF02736;PF02758;PF02793;PF02931;PF02932;PF03045;PF03098;PF03520;PF04505;PF05729;PF05835;PF05923;PF06327;PF06512;PF07562;PF07645;PF07679;PF07686;PF07710;PF07714;PF07885;PF08266;PF08516;PF10409;PF10565;PF10582;PF10613;PF11933;PF12003;PF12444;PF13306;PF13426;PF13516;PF13853;PF13855;PF13895;PF13927
Group	GO:0007154	cell communication	1	11.07	1.36e-23	2.14e-21	115|247|691|3527	PF00001;PF00002;PF00003;PF00007;PF00010;PF00019;PF00027;PF00028;PF00029;PF00038;PF00041;PF00046;PF00048;PF00049;PF00051;PF00057;PF00059;PF00060;PF00061;PF00063;PF00067;PF00071;PF00079;PF00089;PF00090;PF00100;PF00110;PF00123;PF00129;PF00135;PF00147;PF00157;PF00167;PF00193;PF00209;PF00211;PF00230;PF00250;PF00273;PF00292;PF00320;PF00351;PF00386;PF00431;PF00435;PF00474;PF00497;PF00503;PF00520;PF00560;PF00613;PF00615;PF00622;PF00631;PF00683;PF00688;PF00822;PF00870;PF00907;PF00909;PF00930;PF01007;PF01085;PF01094;PF01153;PF01275;PF01391;PF01392;PF01404;PF01421;PF01534;PF01562;PF01833;PF02192;PF02210;PF02214;PF02351;PF02460;PF02736;PF02758;PF02793;PF02931;PF02932;PF03045;PF03098;PF03520;PF04505;PF05729;PF05835;PF05923;PF06327;PF06512;PF07562;PF07645;PF07679;PF07686;PF07710;PF07714;PF07885;PF08266;PF08516;PF10409;PF10565;PF10582;PF10613;PF11933;PF12003;PF12444;PF13306;PF13426;PF13516;PF13853;PF13855;PF13895;PF13927
Group	GO:0042221	response to chemical stimulus	1	10.94	1.33e-22	1.80e-20	106|247|615|3527	PF00001;PF00002;PF00003;PF00010;PF00019;PF00027;PF00040;PF00041;PF00045;PF00046;PF00048;PF00049;PF00053;PF00055;PF00057;PF00059;PF00060;PF00061;PF00063;PF00067;PF00071;PF00079;PF00084;PF00089;PF00090;PF00110;PF00129;PF00135;PF00157;PF00167;PF00201;PF00210;PF00211;PF00230;PF00232;PF00245;PF00250;PF00274;PF00292;PF00320;PF00386;PF00413;PF00431;PF00435;PF00497;PF00503;PF00520;PF00560;PF00613;PF00622;PF00631;PF00685;PF00688;PF00777;PF00858;PF00870;PF00992;PF01085;PF01094;PF01391;PF01392;PF01400;PF01404;PF01410;PF01431;PF01471;PF01534;PF01576;PF01833;PF01979;PF02026;PF02210;PF02736;PF02758;PF02760;PF02793;PF02898;PF02931;PF02932;PF03098;PF03299;PF04505;PF05649;PF05729;PF05923;PF06327;PF06459;PF06512;PF07562;PF07645;PF07679;PF07686;PF07710;PF07714;PF08344;PF10409;PF10565;PF11933;PF12444;PF13426;PF13516;PF13848;PF13853;PF13855;PF13895;PF13927
Group	GO:0040011	locomotion	1	11.38	1.12e-21	1.06e-19	75|247|342|3527	PF00001;PF00002;PF00010;PF00019;PF00022;PF00024;PF00028;PF00041;PF00045;PF00046;PF00048;PF00051;PF00053;PF00055;PF00057;PF00063;PF00071;PF00084;PF00090;PF00100;PF00110;PF00147;PF00157;PF00167;PF00211;PF00250;PF00292;PF00320;PF00413;PF00431;PF00435;PF00520;PF00530;PF00613;PF00688;PF00907;PF00918;PF00930;PF01049;PF01085;PF01153;PF01273;PF01275;PF01391;PF01392;PF01400;PF01404;PF01410;PF01471;PF01534;PF01562;PF01576;PF01833;PF01979;PF02210;PF02214;PF02460;PF02736;PF02886;PF02931;PF02932;PF03045;PF05923;PF07645;PF07679;PF07686;PF07714;PF08344;PF10409;PF12003;PF12444;PF13426;PF13855;PF13895;PF13927
Group	GO:0010646	regulation of cell communication	1	11.34	1.74e-21	1.50e-19	74|247|336|3527	PF00001;PF00002;PF00003;PF00010;PF00019;PF00027;PF00028;PF00040;PF00041;PF00046;PF00048;PF00049;PF00057;PF00059;PF00060;PF00061;PF00063;PF00067;PF00071;PF00079;PF00089;PF00100;PF00110;PF00123;PF00135;PF00167;PF00250;PF00292;PF00320;PF00386;PF00435;PF00497;PF00520;PF00560;PF00615;PF00683;PF00688;PF00870;PF01023;PF01053;PF01085;PF01094;PF01153;PF01391;PF01392;PF01699;PF01833;PF02210;PF02214;PF02460;PF02793;PF02931;PF02932;PF03045;PF03299;PF03736;PF04706;PF05729;PF05835;PF05923;PF07562;PF07645;PF07679;PF07710;PF07714;PF10409;PF10565;PF10613;PF11527;PF12444;PF13516;PF13855;PF13895;PF13927
Group	GO:0048518	positive regulation of biological process	1	10.49	2.30e-21	1.81e-19	109|247|667|3527	PF00001;PF00002;PF00007;PF00010;PF00019;PF00022;PF00024;PF00027;PF00031;PF00038;PF00040;PF00041;PF00046;PF00048;PF00049;PF00051;PF00053;PF00055;PF00057;PF00059;PF00060;PF00061;PF00063;PF00067;PF00071;PF00074;PF00079;PF00084;PF00089;PF00090;PF00100;PF00110;PF00123;PF00125;PF00129;PF00135;PF00147;PF00157;PF00159;PF00167;PF00193;PF00211;PF00230;PF00250;PF00292;PF00320;PF00337;PF00386;PF00431;PF00435;PF00497;PF00503;PF00520;PF00530;PF00560;PF00615;PF00688;PF00870;PF00876;PF00907;PF00930;PF01023;PF01053;PF01085;PF01094;PF01153;PF01275;PF01391;PF01392;PF01404;PF01415;PF01442;PF01454;PF01534;PF01562;PF01699;PF01823;PF01833;PF01979;PF02210;PF02460;PF02758;PF02793;PF02931;PF02932;PF03299;PF03529;PF03736;PF04505;PF05729;PF06327;PF07645;PF07679;PF07686;PF07710;PF07714;PF08214;PF10409;PF10613;PF11357;PF11527;PF12157;PF12444;PF12756;PF13306;PF13516;PF13855;PF13895;PF13927
Group	GO:0051674	localization of cell	1	11.77	2.64e-21	1.92e-19	60|247|229|3527	PF00001;PF00002;PF00010;PF00019;PF00022;PF00024;PF00028;PF00041;PF00045;PF00046;PF00048;PF00051;PF00053;PF00055;PF00057;PF00063;PF00071;PF00084;PF00100;PF00110;PF00147;PF00157;PF00167;PF00250;PF00292;PF00320;PF00413;PF00431;PF00435;PF00520;PF00530;PF00688;PF00907;PF00918;PF00930;PF01049;PF01273;PF01275;PF01404;PF01471;PF01534;PF01562;PF01576;PF01833;PF02210;PF02214;PF02736;PF02886;PF03045;PF05923;PF07645;PF07679;PF07686;PF07714;PF10409;PF12003;PF12444;PF13855;PF13895;PF13927
Group	GO:0023051	regulation of signaling	1	10.39	1.58e-19	9.37e-18	83|247|441|3527	PF00001;PF00002;PF00003;PF00010;PF00019;PF00027;PF00028;PF00040;PF00041;PF00046;PF00048;PF00049;PF00051;PF00057;PF00059;PF00060;PF00061;PF00063;PF00067;PF00071;PF00079;PF00089;PF00090;PF00094;PF00100;PF00110;PF00123;PF00135;PF00157;PF00167;PF00250;PF00292;PF00320;PF00386;PF00435;PF00497;PF00520;PF00560;PF00615;PF00631;PF00683;PF00688;PF00822;PF00870;PF01023;PF01053;PF01085;PF01094;PF01153;PF01391;PF01392;PF01404;PF01534;PF01562;PF01699;PF01833;PF02210;PF02214;PF02351;PF02460;PF02793;PF02931;PF02932;PF03045;PF03299;PF03736;PF04706;PF05729;PF05835;PF05923;PF07562;PF07645;PF07679;PF07710;PF07714;PF10409;PF10613;PF11527;PF12444;PF13516;PF13855;PF13895;PF13927
Group	GO:0009605	response to external stimulus	1	10.62	2.99e-19	1.66e-17	70|247|330|3527	PF00001;PF00010;PF00019;PF00027;PF00028;PF00041;PF00046;PF00048;PF00053;PF00055;PF00059;PF00060;PF00061;PF00063;PF00067;PF00071;PF00089;PF00090;PF00110;PF00123;PF00157;PF00159;PF00167;PF00211;PF00230;PF00273;PF00292;PF00320;PF00431;PF00435;PF00497;PF00503;PF00520;PF00560;PF00613;PF00622;PF00688;PF00858;PF00909;PF01085;PF01094;PF01391;PF01392;PF01400;PF01404;PF01410;PF01510;PF01534;PF01576;PF01833;PF01979;PF02024;PF02210;PF02736;PF02931;PF02932;PF05729;PF05923;PF07645;PF07679;PF07686;PF07714;PF08344;PF10409;PF12444;PF13426;PF13516;PF13855;PF13895;PF13927
Group	GO:0048583	regulation of response to stimulus	1	10.15	3.49e-19	1.83e-17	89|247|503|3527	PF00001;PF00002;PF00010;PF00019;PF00027;PF00028;PF00031;PF00040;PF00041;PF00046;PF00048;PF00049;PF00051;PF00057;PF00059;PF00060;PF00061;PF00063;PF00067;PF00071;PF00079;PF00084;PF00089;PF00090;PF00094;PF00100;PF00110;PF00123;PF00129;PF00135;PF00157;PF00159;PF00167;PF00250;PF00320;PF00386;PF00431;PF00497;PF00520;PF00560;PF00615;PF00631;PF00683;PF00688;PF00822;PF00870;PF01023;PF01053;PF01085;PF01094;PF01153;PF01391;PF01392;PF01404;PF01421;PF01510;PF01534;PF01562;PF01823;PF01833;PF02024;PF02210;PF02214;PF02351;PF02460;PF02758;PF02760;PF02793;PF02931;PF02932;PF03045;PF03299;PF04706;PF04968;PF05729;PF05923;PF07645;PF07679;PF07686;PF07710;PF07714;PF10409;PF11527;PF12444;PF13306;PF13516;PF13855;PF13895;PF13927
Group	GO:0050793	regulation of developmental process	1	10.27	7.19e-19	3.40e-17	78|247|405|3527	PF00001;PF00002;PF00007;PF00010;PF00019;PF00024;PF00028;PF00031;PF00038;PF00041;PF00046;PF00048;PF00049;PF00051;PF00057;PF00060;PF00063;PF00067;PF00071;PF00079;PF00084;PF00089;PF00090;PF00100;PF00110;PF00125;PF00135;PF00147;PF00167;PF00230;PF00250;PF00292;PF00320;PF00386;PF00435;PF00497;PF00503;PF00520;PF00530;PF00560;PF00622;PF00688;PF00870;PF00907;PF01049;PF01085;PF01094;PF01391;PF01392;PF01404;PF01415;PF01510;PF01534;PF01562;PF01576;PF01833;PF01979;PF02210;PF02736;PF02793;PF02931;PF02932;PF03045;PF03145;PF03299;PF03529;PF04505;PF07645;PF07679;PF07686;PF07710;PF07714;PF10409;PF12444;PF13516;PF13855;PF13895;PF13927
Group	GO:0006928	cellular component movement	1	10.30	5.68e-18	2.44e-16	64|247|296|3527	PF00001;PF00002;PF00010;PF00019;PF00022;PF00024;PF00028;PF00038;PF00041;PF00045;PF00046;PF00048;PF00051;PF00053;PF00055;PF00057;PF00063;PF00071;PF00084;PF00100;PF00110;PF00147;PF00157;PF00167;PF00250;PF00292;PF00320;PF00413;PF00431;PF00435;PF00520;PF00530;PF00613;PF00688;PF00907;PF00918;PF00930;PF00992;PF01049;PF01273;PF01275;PF01404;PF01471;PF01534;PF01562;PF01576;PF01833;PF02210;PF02214;PF02736;PF02886;PF03045;PF05716;PF05923;PF07645;PF07679;PF07686;PF07714;PF10409;PF12003;PF12444;PF13855;PF13895;PF13927
Group	GO:0048519	negative regulation of biological process	1	9.08	9.37e-17	3.55e-15	102|247|681|3527	PF00001;PF00002;PF00003;PF00010;PF00019;PF00024;PF00028;PF00031;PF00041;PF00042;PF00046;PF00048;PF00049;PF00051;PF00057;PF00060;PF00061;PF00067;PF00071;PF00074;PF00079;PF00084;PF00089;PF00090;PF00100;PF00110;PF00125;PF00147;PF00167;PF00210;PF00230;PF00250;PF00273;PF00292;PF00320;PF00386;PF00431;PF00435;PF00497;PF00503;PF00520;PF00530;PF00560;PF00613;PF00615;PF00622;PF00683;PF00688;PF00751;PF00870;PF00907;PF00930;PF01053;PF01085;PF01094;PF01153;PF01271;PF01391;PF01392;PF01400;PF01404;PF01415;PF01454;PF01510;PF01534;PF01562;PF01699;PF01823;PF01833;PF01858;PF01979;PF02024;PF02026;PF02210;PF02214;PF02351;PF02460;PF02793;PF02898;PF02931;PF02932;PF03045;PF03299;PF04505;PF04706;PF05729;PF05923;PF06459;PF07562;PF07645;PF07679;PF07686;PF07710;PF07714;PF08934;PF10409;PF10613;PF12444;PF13516;PF13855;PF13895;PF13927
Group	GO:0065009	regulation of molecular function	1	9.25	7.48e-16	2.53e-14	72|247|396|3527	PF00001;PF00002;PF00003;PF00010;PF00019;PF00027;PF00028;PF00031;PF00041;PF00046;PF00048;PF00049;PF00050;PF00051;PF00057;PF00063;PF00067;PF00071;PF00074;PF00079;PF00089;PF00090;PF00100;PF00110;PF00123;PF00135;PF00147;PF00167;PF00211;PF00250;PF00320;PF00386;PF00503;PF00520;PF00615;PF00622;PF00631;PF00688;PF00822;PF00870;PF00992;PF01053;PF01094;PF01391;PF01392;PF01404;PF01442;PF01534;PF01858;PF02026;PF02210;PF02736;PF02758;PF02793;PF02898;PF02931;PF02932;PF03299;PF05729;PF06327;PF06459;PF07645;PF07679;PF07714;PF08266;PF08374;PF08934;PF11357;PF13516;PF13855;PF13895;PF13927
Group	GO:0000902	cell morphogenesis	1	9.37	3.37e-15	9.66e-14	56|247|265|3527	PF00010;PF00019;PF00024;PF00028;PF00041;PF00046;PF00053;PF00055;PF00061;PF00063;PF00071;PF00090;PF00100;PF00110;PF00147;PF00157;PF00167;PF00250;PF00292;PF00320;PF00431;PF00435;PF00520;PF00530;PF00560;PF00688;PF00918;PF01049;PF01085;PF01153;PF01275;PF01391;PF01392;PF01400;PF01404;PF01410;PF01442;PF01534;PF01576;PF01833;PF01979;PF02210;PF02736;PF03045;PF05729;PF05923;PF07645;PF07679;PF07714;PF08344;PF10162;PF12003;PF12444;PF13855;PF13895;PF13927
Group	GO:0051128	regulation of cellular component organization	1	8.95	1.20e-14	3.16e-13	63|247|333|3527	PF00001;PF00010;PF00019;PF00022;PF00024;PF00028;PF00031;PF00038;PF00041;PF00046;PF00048;PF00049;PF00059;PF00060;PF00061;PF00063;PF00071;PF00089;PF00100;PF00110;PF00135;PF00167;PF00250;PF00292;PF00320;PF00386;PF00431;PF00435;PF00497;PF00503;PF00520;PF00560;PF00622;PF00688;PF00870;PF00930;PF01094;PF01275;PF01391;PF01392;PF01404;PF01454;PF01562;PF01576;PF01833;PF01979;PF02210;PF02736;PF02931;PF02932;PF04505;PF04968;PF05923;PF07645;PF07679;PF07686;PF07710;PF07714;PF10409;PF13516;PF13855;PF13895;PF13927
Group	GO:0002376	immune system process	1	8.70	5.31e-14	1.26e-12	62|247|334|3527	PF00001;PF00010;PF00019;PF00041;PF00042;PF00046;PF00048;PF00057;PF00059;PF00063;PF00071;PF00079;PF00084;PF00089;PF00090;PF00100;PF00110;PF00129;PF00167;PF00210;PF00250;PF00320;PF00337;PF00386;PF00431;PF00560;PF00613;PF00688;PF00870;PF00879;PF00907;PF00930;PF01023;PF01271;PF01273;PF01391;PF01392;PF01404;PF01510;PF01534;PF01562;PF01576;PF01823;PF02192;PF02736;PF02758;PF02886;PF02931;PF02932;PF04505;PF05729;PF07645;PF07679;PF07686;PF07710;PF07714;PF10409;PF13306;PF13516;PF13855;PF13895;PF13927
Group	GO:0009790	embryo development	1	8.54	2.22e-13	4.99e-12	57|247|299|3527	PF00001;PF00010;PF00019;PF00028;PF00029;PF00041;PF00046;PF00051;PF00053;PF00057;PF00063;PF00071;PF00089;PF00100;PF00110;PF00125;PF00157;PF00167;PF00250;PF00292;PF00320;PF00435;PF00503;PF00520;PF00560;PF00615;PF00622;PF00688;PF00870;PF00907;PF01049;PF01085;PF01347;PF01391;PF01392;PF01534;PF01576;PF02210;PF02460;PF02736;PF03045;PF03299;PF03520;PF03529;PF05923;PF07645;PF07679;PF07686;PF07710;PF07714;PF08266;PF10582;PF12413;PF12444;PF13306;PF13895;PF13927
Group	GO:0032990	cell part morphogenesis	1	8.45	1.74e-12	3.51e-11	45|247|210|3527	PF00024;PF00028;PF00041;PF00046;PF00053;PF00055;PF00061;PF00063;PF00090;PF00110;PF00147;PF00157;PF00250;PF00292;PF00431;PF00435;PF00520;PF00688;PF00918;PF01049;PF01085;PF01153;PF01275;PF01391;PF01400;PF01404;PF01410;PF01442;PF01534;PF01576;PF01833;PF01979;PF02210;PF02736;PF05729;PF05923;PF07645;PF07679;PF07714;PF08344;PF10162;PF12003;PF13855;PF13895;PF13927
Group	GO:0051716	cellular response to stimulus	1	7.28	5.26e-12	9.76e-11	107|247|853|3527	PF00001;PF00002;PF00003;PF00010;PF00019;PF00027;PF00038;PF00040;PF00041;PF00046;PF00048;PF00049;PF00051;PF00057;PF00059;PF00060;PF00061;PF00063;PF00067;PF00071;PF00079;PF00089;PF00090;PF00100;PF00110;PF00123;PF00125;PF00129;PF00147;PF00157;PF00167;PF00193;PF00201;PF00211;PF00230;PF00245;PF00250;PF00273;PF00292;PF00320;PF00386;PF00431;PF00435;PF00497;PF00503;PF00520;PF00560;PF00613;PF00615;PF00622;PF00631;PF00683;PF00685;PF00688;PF00777;PF00870;PF00909;PF01085;PF01094;PF01153;PF01391;PF01392;PF01404;PF01410;PF01431;PF01442;PF01534;PF01562;PF01833;PF01979;PF02026;PF02192;PF02351;PF02460;PF02736;PF02758;PF02760;PF02793;PF02931;PF02932;PF03045;PF03098;PF03299;PF05649;PF05729;PF05923;PF06327;PF06459;PF07562;PF07645;PF07679;PF07686;PF07710;PF07714;PF10409;PF10565;PF10613;PF12003;PF12444;PF13306;PF13426;PF13516;PF13848;PF13853;PF13855;PF13895;PF13927
Group	GO:0030030	cell projection organization	1	7.97	1.09e-11	1.81e-10	48|247|246|3527	PF00019;PF00024;PF00028;PF00041;PF00046;PF00053;PF00055;PF00061;PF00063;PF00071;PF00090;PF00110;PF00135;PF00147;PF00157;PF00250;PF00292;PF00431;PF00435;PF00520;PF00688;PF00918;PF01049;PF01085;PF01153;PF01275;PF01391;PF01400;PF01404;PF01410;PF01442;PF01534;PF01576;PF01833;PF01979;PF02210;PF02736;PF05729;PF05923;PF07645;PF07679;PF07714;PF08344;PF10162;PF12003;PF13855;PF13895;PF13927
Group	GO:0000003	reproduction	1	7.22	9.44e-11	1.33e-09	64|247|412|3527	PF00001;PF00007;PF00010;PF00019;PF00022;PF00028;PF00041;PF00045;PF00046;PF00049;PF00053;PF00055;PF00060;PF00063;PF00071;PF00079;PF00084;PF00089;PF00100;PF00110;PF00125;PF00135;PF00147;PF00167;PF00188;PF00193;PF00211;PF00245;PF00250;PF00320;PF00351;PF00413;PF00435;PF00497;PF00520;PF00538;PF00560;PF00622;PF00688;PF00751;PF00858;PF00870;PF01070;PF01085;PF01094;PF01392;PF01421;PF01471;PF01534;PF01562;PF02460;PF02931;PF02932;PF05236;PF07679;PF07686;PF07714;PF08516;PF11357;PF12444;PF13516;PF13855;PF13895;PF13927
Group	GO:0006950	response to stress	1	6.81	1.70e-10	2.24e-09	91|247|709|3527	PF00001;PF00010;PF00019;PF00024;PF00027;PF00031;PF00040;PF00041;PF00042;PF00045;PF00048;PF00049;PF00051;PF00057;PF00059;PF00060;PF00061;PF00063;PF00067;PF00071;PF00074;PF00079;PF00084;PF00089;PF00094;PF00110;PF00125;PF00129;PF00147;PF00167;PF00193;PF00230;PF00232;PF00250;PF00273;PF00274;PF00320;PF00386;PF00413;PF00435;PF00503;PF00520;PF00530;PF00560;PF00622;PF00688;PF00868;PF00870;PF00879;PF00909;PF00927;PF01023;PF01094;PF01273;PF01391;PF01404;PF01410;PF01442;PF01471;PF01510;PF01534;PF01576;PF01823;PF01826;PF01833;PF01841;PF01979;PF02192;PF02210;PF02736;PF02758;PF02886;PF02931;PF02932;PF03098;PF04505;PF05729;PF07645;PF07679;PF07686;PF07710;PF07714;PF08742;PF10409;PF10613;PF13306;PF13516;PF13848;PF13855;PF13895;PF13927
Group	GO:0051234	establishment of localization	1	6.67	2.80e-10	3.39e-09	97|247|785|3527	PF00001;PF00010;PF00019;PF00022;PF00027;PF00038;PF00040;PF00041;PF00042;PF00046;PF00048;PF00049;PF00053;PF00057;PF00059;PF00060;PF00061;PF00063;PF00067;PF00068;PF00071;PF00084;PF00089;PF00100;PF00123;PF00135;PF00151;PF00167;PF00209;PF00211;PF00230;PF00318;PF00320;PF00386;PF00431;PF00435;PF00474;PF00497;PF00503;PF00520;PF00560;PF00613;PF00615;PF00622;PF00683;PF00688;PF00858;PF00870;PF00876;PF00909;PF01007;PF01062;PF01094;PF01347;PF01391;PF01442;PF01562;PF01699;PF01740;PF01758;PF01813;PF01833;PF02026;PF02210;PF02214;PF02460;PF02736;PF02886;PF02931;PF02932;PF03024;PF03137;PF03520;PF03765;PF04505;PF04548;PF04916;PF05835;PF06327;PF06459;PF06512;PF07645;PF07679;PF07686;PF07710;PF07714;PF07885;PF08344;PF08434;PF09315;PF11933;PF13385;PF13426;PF13516;PF13855;PF13895;PF13927
Group	GO:0031323	regulation of cellular metabolic process	1	5.10	7.37e-07	4.20e-06	94|247|867|3527	PF00001;PF00002;PF00003;PF00010;PF00019;PF00027;PF00028;PF00038;PF00041;PF00042;PF00046;PF00048;PF00049;PF00050;PF00051;PF00057;PF00059;PF00061;PF00063;PF00067;PF00071;PF00079;PF00089;PF00100;PF00110;PF00123;PF00125;PF00151;PF00157;PF00167;PF00211;PF00250;PF00292;PF00320;PF00386;PF00435;PF00503;PF00520;PF00530;PF00560;PF00615;PF00631;PF00688;PF00751;PF00870;PF00907;PF00956;PF00992;PF01053;PF01070;PF01085;PF01094;PF01391;PF01392;PF01404;PF01454;PF01534;PF01833;PF01858;PF02210;PF02736;PF02758;PF02793;PF02931;PF02932;PF03299;PF03370;PF03529;PF04845;PF05236;PF05729;PF05923;PF06327;PF07562;PF07645;PF07679;PF07686;PF07710;PF07714;PF08214;PF08266;PF08374;PF08934;PF11357;PF11527;PF12157;PF12413;PF12444;PF12756;PF13306;PF13516;PF13855;PF13895;PF13927
Group	GO:0007163	establishment or maintenance of cell polarity	1	5.85	1.54e-06	7.98e-06	20|247|88|3527	PF00022;PF00028;PF00041;PF00053;PF00057;PF00063;PF00071;PF00110;PF00167;PF00230;PF00435;PF01049;PF01404;PF02210;PF02736;PF05923;PF07679;PF07714;PF13855;PF13895
Group	GO:0033036	macromolecule localization	1	5.10	2.64e-06	1.25e-05	48|247|354|3527	PF00001;PF00019;PF00038;PF00041;PF00050;PF00053;PF00057;PF00060;PF00061;PF00063;PF00068;PF00071;PF00100;PF00110;PF00135;PF00151;PF00167;PF00292;PF00318;PF00386;PF00435;PF00520;PF00560;PF00683;PF00688;PF00870;PF01347;PF01391;PF01392;PF01442;PF01534;PF02210;PF02460;PF02736;PF03024;PF03045;PF03765;PF04505;PF04548;PF07645;PF07679;PF07710;PF07714;PF10409;PF11527;PF13516;PF13855;PF13895
Group	GO:0080090	regulation of primary metabolic process	1	4.72	4.14e-06	1.82e-05	91|247|861|3527	PF00001;PF00002;PF00003;PF00010;PF00019;PF00024;PF00027;PF00038;PF00041;PF00042;PF00046;PF00048;PF00049;PF00050;PF00051;PF00057;PF00059;PF00061;PF00063;PF00067;PF00071;PF00079;PF00084;PF00089;PF00100;PF00110;PF00123;PF00125;PF00157;PF00167;PF00211;PF00250;PF00292;PF00320;PF00386;PF00435;PF00503;PF00530;PF00560;PF00615;PF00631;PF00688;PF00751;PF00870;PF00907;PF00956;PF00992;PF01053;PF01085;PF01094;PF01391;PF01392;PF01404;PF01442;PF01454;PF01534;PF01833;PF01858;PF02210;PF02351;PF02736;PF02758;PF02793;PF02931;PF02932;PF03299;PF03370;PF03529;PF04845;PF05236;PF05729;PF05923;PF06327;PF07562;PF07645;PF07679;PF07686;PF07710;PF07714;PF08214;PF08934;PF11357;PF11527;PF12157;PF12413;PF12444;PF12756;PF13516;PF13855;PF13895;PF13927
Group	GO:0060255	regulation of macromolecule metabolic process	1	3.86	1.24e-04	3.54e-04	86|247|868|3527	PF00001;PF00010;PF00019;PF00024;PF00027;PF00038;PF00041;PF00042;PF00046;PF00048;PF00049;PF00050;PF00051;PF00057;PF00059;PF00061;PF00067;PF00071;PF00079;PF00084;PF00089;PF00100;PF00110;PF00123;PF00125;PF00151;PF00157;PF00167;PF00193;PF00211;PF00250;PF00292;PF00320;PF00386;PF00435;PF00530;PF00560;PF00615;PF00688;PF00751;PF00870;PF00907;PF00956;PF01053;PF01085;PF01391;PF01392;PF01400;PF01404;PF01415;PF01454;PF01534;PF01833;PF01858;PF02210;PF02351;PF02758;PF02931;PF02932;PF03299;PF03370;PF03529;PF04553;PF04845;PF05236;PF05729;PF05923;PF06327;PF07645;PF07679;PF07686;PF07710;PF07714;PF08214;PF08934;PF10409;PF11357;PF11527;PF12157;PF12413;PF12444;PF12756;PF13516;PF13855;PF13895;PF13927
Group	GO:0051171	regulation of nitrogen compound metabolic process	1	3.87	1.49e-04	4.18e-04	68|247|647|3527	PF00001;PF00002;PF00003;PF00010;PF00019;PF00027;PF00038;PF00041;PF00042;PF00046;PF00048;PF00049;PF00063;PF00067;PF00071;PF00089;PF00100;PF00110;PF00123;PF00125;PF00157;PF00167;PF00211;PF00250;PF00292;PF00320;PF00386;PF00435;PF00503;PF00530;PF00615;PF00631;PF00688;PF00751;PF00870;PF00907;PF00992;PF01053;PF01085;PF01094;PF01391;PF01392;PF01404;PF01534;PF01833;PF01858;PF02736;PF02758;PF02793;PF03299;PF03529;PF04845;PF05236;PF05729;PF06327;PF07562;PF07645;PF07679;PF07710;PF07714;PF08214;PF12157;PF12413;PF12444;PF12756;PF13516;PF13855;PF13895
Group	GO:0051641	cellular localization	1	3.88	1.74e-04	4.67e-04	55|247|494|3527	PF00001;PF00010;PF00019;PF00022;PF00027;PF00038;PF00041;PF00046;PF00048;PF00050;PF00053;PF00063;PF00071;PF00089;PF00100;PF00110;PF00135;PF00167;PF00210;PF00273;PF00292;PF00318;PF00386;PF00435;PF00520;PF00560;PF00615;PF00622;PF00683;PF00688;PF00870;PF01391;PF01392;PF02026;PF02210;PF02460;PF02736;PF02931;PF02932;PF03024;PF04505;PF04548;PF05835;PF06459;PF07645;PF07679;PF07710;PF07714;PF11527;PF12756;PF13385;PF13516;PF13855;PF13895;PF13927
Group	GO:0009889	regulation of biosynthetic process	1	3.71	2.57e-04	6.63e-04	67|247|646|3527	PF00001;PF00002;PF00003;PF00007;PF00010;PF00019;PF00038;PF00042;PF00046;PF00048;PF00049;PF00059;PF00061;PF00067;PF00089;PF00100;PF00110;PF00123;PF00125;PF00157;PF00167;PF00211;PF00250;PF00292;PF00320;PF00386;PF00435;PF00503;PF00520;PF00530;PF00560;PF00688;PF00751;PF00870;PF00907;PF01053;PF01085;PF01094;PF01391;PF01392;PF01534;PF01833;PF01858;PF02758;PF02793;PF03299;PF03370;PF03529;PF04845;PF05236;PF05729;PF06327;PF07562;PF07645;PF07679;PF07686;PF07710;PF07714;PF08214;PF12157;PF12413;PF12444;PF12756;PF13306;PF13516;PF13855;PF13895
Group	GO:0019538	protein metabolic process	1	3.08	1.68e-03	2.92e-03	81|247|869|3527	PF00001;PF00010;PF00019;PF00022;PF00027;PF00040;PF00041;PF00045;PF00048;PF00049;PF00051;PF00057;PF00059;PF00063;PF00071;PF00084;PF00089;PF00090;PF00094;PF00110;PF00167;PF00246;PF00252;PF00318;PF00386;PF00413;PF00431;PF00530;PF00538;PF00572;PF00613;PF00615;PF00622;PF00685;PF00688;PF00777;PF00868;PF00927;PF01053;PF01390;PF01391;PF01400;PF01404;PF01421;PF01431;PF01442;PF01471;PF01531;PF01562;PF01576;PF01762;PF01823;PF01841;PF02210;PF02214;PF02244;PF02736;PF02898;PF03145;PF03567;PF04300;PF04922;PF04968;PF05649;PF05986;PF07645;PF07679;PF07686;PF07714;PF08214;PF08516;PF10409;PF12157;PF12444;PF12529;PF13426;PF13516;PF13848;PF13855;PF13895;PF13927
Group	GO:0007600	sensory perception	2	13.49	1.69e-22	2.00e-20	40|247|96|3527	PF00001;PF00003;PF00024;PF00027;PF00028;PF00029;PF00030;PF00046;PF00053;PF00055;PF00060;PF00063;PF00071;PF00089;PF00100;PF00157;PF00497;PF00503;PF00520;PF00615;PF00858;PF00907;PF01094;PF01391;PF01410;PF01431;PF01534;PF02931;PF02932;PF03299;PF05649;PF07562;PF07679;PF07686;PF07714;PF10582;PF13385;PF13853;PF13895;PF13927
Group	GO:0044057	regulation of system process	2	13.11	2.30e-22	2.42e-20	44|247|118|3527	PF00001;PF00003;PF00019;PF00027;PF00041;PF00046;PF00048;PF00060;PF00063;PF00068;PF00071;PF00135;PF00230;PF00351;PF00386;PF00435;PF00497;PF00503;PF00520;PF00615;PF00688;PF00992;PF01007;PF01094;PF01391;PF01699;PF01833;PF02210;PF02214;PF02736;PF02898;PF02931;PF02932;PF03520;PF03736;PF05835;PF06512;PF07562;PF07679;PF07686;PF10613;PF11933;PF13426;PF13855
Group	GO:0016477	cell migration	2	11.85	1.00e-20	6.79e-19	53|247|185|3527	PF00001;PF00002;PF00010;PF00019;PF00028;PF00041;PF00045;PF00046;PF00048;PF00053;PF00055;PF00057;PF00063;PF00071;PF00100;PF00110;PF00147;PF00157;PF00167;PF00250;PF00292;PF00320;PF00413;PF00431;PF00435;PF00530;PF00688;PF00907;PF00918;PF00930;PF01049;PF01275;PF01404;PF01471;PF01534;PF01562;PF01576;PF01833;PF02210;PF02214;PF02736;PF03045;PF05923;PF07645;PF07679;PF07686;PF07714;PF10409;PF12003;PF12444;PF13855;PF13895;PF13927
Group	GO:0007610	behavior	2	11.87	4.88e-20	3.08e-18	47|247|151|3527	PF00001;PF00003;PF00010;PF00027;PF00028;PF00046;PF00057;PF00060;PF00061;PF00063;PF00071;PF00089;PF00135;PF00159;PF00209;PF00250;PF00351;PF00435;PF00497;PF00520;PF00530;PF00560;PF00858;PF00876;PF00907;PF00918;PF01023;PF01094;PF01421;PF01562;PF01699;PF02024;PF02210;PF02214;PF02931;PF02932;PF06512;PF07562;PF07714;PF08516;PF10565;PF10613;PF11933;PF13306;PF13855;PF13895;PF13927
Group	GO:0051240	positive regulation of multicellular organismal process	2	12.10	4.40e-19	2.19e-17	37|247|98|3527	PF00001;PF00019;PF00027;PF00038;PF00046;PF00048;PF00060;PF00079;PF00089;PF00100;PF00110;PF00123;PF00135;PF00230;PF00292;PF00320;PF00386;PF00520;PF00560;PF00688;PF00907;PF01094;PF01391;PF01699;PF02210;PF02460;PF02758;PF03299;PF03736;PF05729;PF07645;PF07679;PF07714;PF10613;PF12444;PF13516;PF13855
Group	GO:0051046	regulation of secretion	2	11.70	4.03e-18	1.82e-16	36|247|98|3527	PF00001;PF00002;PF00003;PF00019;PF00027;PF00040;PF00046;PF00048;PF00059;PF00061;PF00071;PF00074;PF00100;PF00123;PF00230;PF00250;PF00292;PF00320;PF00520;PF00622;PF00688;PF01094;PF01833;PF02214;PF02758;PF02793;PF02931;PF02932;PF03299;PF05729;PF07686;PF07714;PF10613;PF13516;PF13895;PF13927
Group	GO:2000145	regulation of cell motility	2	11.20	3.86e-17	1.59e-15	36|247|104|3527	PF00001;PF00007;PF00019;PF00041;PF00045;PF00046;PF00048;PF00055;PF00061;PF00071;PF00084;PF00090;PF00100;PF00110;PF00147;PF00167;PF00292;PF00320;PF00386;PF00413;PF00688;PF00907;PF01391;PF01392;PF01471;PF01562;PF01833;PF01979;PF07645;PF07679;PF07714;PF10409;PF12444;PF13855;PF13895;PF13927
Group	GO:0032101	regulation of response to external stimulus	2	11.23	6.59e-17	2.60e-15	34|247|94|3527	PF00001;PF00010;PF00019;PF00027;PF00031;PF00041;PF00048;PF00051;PF00060;PF00061;PF00067;PF00079;PF00084;PF00089;PF00100;PF00110;PF00159;PF00320;PF00386;PF00497;PF00688;PF01094;PF01391;PF01421;PF01562;PF01833;PF02024;PF02210;PF02758;PF05729;PF07679;PF07714;PF13855;PF13895
Group	GO:0071310	cellular response to organic substance	2	9.86	3.62e-16	1.32e-14	54|247|237|3527	PF00001;PF00002;PF00019;PF00041;PF00046;PF00048;PF00049;PF00060;PF00061;PF00067;PF00071;PF00110;PF00129;PF00167;PF00201;PF00211;PF00230;PF00245;PF00250;PF00292;PF00320;PF00386;PF00431;PF00497;PF00520;PF00560;PF00613;PF00622;PF00631;PF00688;PF00777;PF01094;PF01391;PF01410;PF01431;PF01979;PF02026;PF02758;PF02760;PF02793;PF03098;PF05649;PF05729;PF06327;PF06459;PF07679;PF07686;PF07714;PF10409;PF12444;PF13516;PF13855;PF13895;PF13927
Group	GO:0050878	regulation of body fluid levels	2	11.06	4.03e-16	1.41e-14	31|247|82|3527	PF00001;PF00024;PF00027;PF00041;PF00042;PF00048;PF00051;PF00059;PF00067;PF00079;PF00084;PF00089;PF00094;PF00147;PF00230;PF00320;PF00503;PF00520;PF00868;PF00927;PF01094;PF01826;PF01841;PF03299;PF07679;PF07686;PF07714;PF08344;PF08742;PF13895;PF13927
Group	GO:0030198	extracellular matrix organization	2	11.25	8.60e-16	2.81e-14	27|247|63|3527	PF00010;PF00019;PF00041;PF00045;PF00053;PF00055;PF00057;PF00063;PF00079;PF00089;PF00090;PF00147;PF00250;PF00413;PF00530;PF00688;PF01391;PF01392;PF01410;PF01421;PF01471;PF01562;PF02210;PF05986;PF07679;PF13855;PF13895
Group	GO:0060341	regulation of cellular localization	2	10.19	9.93e-16	3.13e-14	41|247|146|3527	PF00001;PF00002;PF00003;PF00019;PF00027;PF00046;PF00048;PF00059;PF00061;PF00063;PF00071;PF00074;PF00100;PF00123;PF00250;PF00292;PF00320;PF00386;PF00520;PF00615;PF00622;PF00688;PF01094;PF01391;PF01392;PF01534;PF01833;PF02214;PF02351;PF02758;PF02793;PF02931;PF02932;PF03299;PF05729;PF07686;PF07714;PF13516;PF13855;PF13895;PF13927
Group	GO:0050817	coagulation	2	11.13	1.40e-15	4.26e-14	27|247|64|3527	PF00001;PF00024;PF00027;PF00041;PF00042;PF00048;PF00051;PF00059;PF00071;PF00079;PF00084;PF00089;PF00094;PF00147;PF00320;PF00503;PF00520;PF00868;PF00927;PF01826;PF01841;PF07679;PF07686;PF07714;PF08742;PF13895;PF13927
Group	GO:0010562	positive regulation of phosphorus metabolic process	2	10.41	3.26e-15	9.65e-14	33|247|99|3527	PF00001;PF00010;PF00019;PF00041;PF00048;PF00049;PF00051;PF00057;PF00071;PF00100;PF00110;PF00167;PF00211;PF00386;PF00615;PF00688;PF01391;PF01392;PF01534;PF02210;PF02931;PF02932;PF06327;PF07645;PF07679;PF07714;PF11357;PF11527;PF12444;PF13516;PF13855;PF13895;PF13927
Group	GO:0001654	eye development	2	10.08	7.82e-15	2.18e-13	35|247|114|3527	PF00010;PF00019;PF00028;PF00030;PF00038;PF00041;PF00046;PF00053;PF00063;PF00071;PF00110;PF00157;PF00167;PF00230;PF00246;PF00250;PF00292;PF00503;PF00520;PF00688;PF01049;PF01153;PF01275;PF01392;PF01404;PF01534;PF02210;PF02736;PF03299;PF03529;PF07679;PF07714;PF10409;PF12444;PF13895
Group	GO:0042060	wound healing	2	10.34	1.12e-14	3.03e-13	30|247|85|3527	PF00001;PF00024;PF00027;PF00041;PF00042;PF00051;PF00061;PF00063;PF00071;PF00084;PF00089;PF00094;PF00110;PF00193;PF00320;PF00435;PF00503;PF00520;PF00622;PF00868;PF00927;PF01410;PF01576;PF01826;PF01841;PF02736;PF07679;PF07686;PF07714;PF08742
Group	GO:0043583	ear development	2	10.88	2.02e-14	5.16e-13	23|247|50|3527	PF00002;PF00010;PF00028;PF00046;PF00049;PF00063;PF00089;PF00129;PF00157;PF00167;PF00292;PF00320;PF00907;PF01392;PF01534;PF03299;PF03529;PF07645;PF07679;PF07714;PF12444;PF13385;PF13895
Group	GO:0030900	forebrain development	2	10.27	2.09e-14	5.20e-13	29|247|81|3527	PF00001;PF00010;PF00019;PF00041;PF00046;PF00057;PF00060;PF00110;PF00123;PF00157;PF00167;PF00230;PF00246;PF00250;PF00292;PF00497;PF00688;PF01085;PF01094;PF01404;PF02210;PF03299;PF03529;PF07645;PF07679;PF07714;PF13855;PF13895;PF13927
Group	GO:0051347	positive regulation of transferase activity	2	10.21	3.84e-14	9.33e-13	28|247|77|3527	PF00001;PF00019;PF00041;PF00048;PF00049;PF00057;PF00071;PF00100;PF00110;PF00167;PF00211;PF00386;PF00615;PF00688;PF01391;PF01534;PF02210;PF02931;PF02932;PF06327;PF07645;PF07679;PF07714;PF11357;PF13516;PF13855;PF13895;PF13927
Group	GO:0071495	cellular response to endogenous stimulus	2	9.54	6.55e-14	1.51e-12	36|247|128|3527	PF00001;PF00002;PF00019;PF00041;PF00046;PF00048;PF00049;PF00060;PF00061;PF00071;PF00110;PF00167;PF00201;PF00211;PF00230;PF00250;PF00320;PF00386;PF00497;PF00560;PF00613;PF00631;PF00688;PF01094;PF01391;PF01410;PF02793;PF05729;PF06327;PF07679;PF07714;PF10409;PF12444;PF13516;PF13855;PF13895
Group	GO:0006955	immune response	2	9.19	2.43e-13	5.34e-12	37|247|140|3527	PF00001;PF00041;PF00048;PF00057;PF00059;PF00071;PF00079;PF00084;PF00089;PF00090;PF00100;PF00129;PF00210;PF00320;PF00337;PF00386;PF00431;PF00560;PF00870;PF00879;PF01273;PF01391;PF01404;PF01510;PF01823;PF02886;PF04505;PF05729;PF07645;PF07679;PF07686;PF07714;PF10409;PF13516;PF13855;PF13895;PF13927
Group	GO:0001568	blood vessel development	2	9.32	5.71e-13	1.23e-11	31|247|103|3527	PF00001;PF00010;PF00019;PF00029;PF00046;PF00048;PF00063;PF00074;PF00090;PF00100;PF00110;PF00147;PF00167;PF00530;PF00688;PF00907;PF00992;PF01085;PF01392;PF01404;PF01410;PF01534;PF01833;PF02210;PF03299;PF07645;PF07679;PF07686;PF07714;PF10582;PF13895
Group	GO:0060485	mesenchyme development	2	9.94	6.35e-13	1.34e-11	23|247|57|3527	PF00001;PF00010;PF00019;PF00046;PF00100;PF00110;PF00167;PF00250;PF00292;PF00320;PF00431;PF00530;PF00688;PF00907;PF01392;PF01534;PF01833;PF03299;PF07645;PF07679;PF07714;PF12444;PF13895
Group	GO:0010769	regulation of cell morphogenesis involved in differentiation	2	9.76	8.77e-13	1.80e-11	24|247|63|3527	PF00019;PF00041;PF00060;PF00089;PF00110;PF00167;PF00292;PF00435;PF00497;PF00520;PF00560;PF00688;PF01094;PF01404;PF01562;PF01833;PF02210;PF02931;PF02932;PF07679;PF13516;PF13855;PF13895;PF13927
Group	GO:0042391	regulation of membrane potential	2	9.21	3.50e-12	6.90e-11	26|247|78|3527	PF00010;PF00041;PF00060;PF00135;PF00497;PF00520;PF00822;PF00930;PF01007;PF01094;PF01275;PF01421;PF01562;PF02210;PF02214;PF02931;PF02932;PF06512;PF07679;PF07686;PF07714;PF08516;PF10565;PF10613;PF11933;PF13895
Group	GO:0051241	negative regulation of multicellular organismal process	2	9.33	4.23e-12	8.16e-11	24|247|67|3527	PF00001;PF00019;PF00031;PF00041;PF00051;PF00060;PF00061;PF00079;PF00089;PF00110;PF00250;PF00386;PF00688;PF00907;PF01094;PF01391;PF01510;PF01699;PF02931;PF02932;PF07645;PF10409;PF10613;PF12444
Group	GO:0007268	synaptic transmission	2	8.54	5.12e-12	9.69e-11	36|247|146|3527	PF00001;PF00003;PF00041;PF00060;PF00063;PF00071;PF00135;PF00209;PF00211;PF00351;PF00386;PF00435;PF00474;PF00497;PF00520;PF00622;PF00631;PF01007;PF01094;PF01392;PF01404;PF02210;PF02214;PF02931;PF02932;PF04505;PF05835;PF06327;PF07562;PF07679;PF07714;PF07885;PF10565;PF10613;PF13426;PF13855
Group	GO:0055123	digestive system development	2	9.77	6.11e-12	1.09e-10	19|247|42|3527	PF00010;PF00019;PF00041;PF00046;PF00049;PF00250;PF00320;PF00688;PF00870;PF00907;PF01085;PF01392;PF01534;PF07679;PF07686;PF07710;PF07714;PF13895;PF13927
Group	GO:0001763	morphogenesis of a branching structure	2	9.23	6.13e-12	1.09e-10	24|247|68|3527	PF00001;PF00010;PF00019;PF00045;PF00046;PF00049;PF00090;PF00110;PF00167;PF00193;PF00292;PF00413;PF00435;PF00688;PF00870;PF01085;PF01404;PF01471;PF01833;PF07645;PF07679;PF07714;PF12444;PF13855
Group	GO:0032270	positive regulation of cellular protein metabolic process	2	8.51	6.81e-12	1.19e-10	35|247|140|3527	PF00001;PF00010;PF00019;PF00041;PF00048;PF00049;PF00051;PF00057;PF00071;PF00100;PF00110;PF00167;PF00211;PF00386;PF00615;PF00688;PF00870;PF01391;PF01454;PF01534;PF02210;PF02931;PF02932;PF06327;PF07645;PF07679;PF07710;PF07714;PF11357;PF11527;PF12444;PF13516;PF13855;PF13895;PF13927
Group	GO:0051050	positive regulation of transport	2	8.85	8.24e-12	1.42e-10	28|247|93|3527	PF00001;PF00019;PF00031;PF00040;PF00046;PF00048;PF00049;PF00059;PF00071;PF00074;PF00100;PF00110;PF00123;PF00230;PF00320;PF00386;PF00688;PF01094;PF01391;PF02210;PF02758;PF05729;PF07686;PF07714;PF10613;PF13516;PF13855;PF13895
Group	GO:0042981	regulation of apoptotic process	2	8.05	8.65e-12	1.46e-10	47|247|236|3527	PF00001;PF00010;PF00019;PF00024;PF00041;PF00046;PF00048;PF00049;PF00051;PF00060;PF00071;PF00090;PF00110;PF00147;PF00157;PF00167;PF00230;PF00250;PF00273;PF00292;PF00320;PF00386;PF00497;PF00520;PF00613;PF00688;PF00870;PF00907;PF01053;PF01094;PF01391;PF01392;PF01404;PF01415;PF01442;PF02351;PF02758;PF03299;PF05729;PF07679;PF07710;PF07714;PF10409;PF12444;PF13855;PF13895;PF13927
Group	GO:0009968	negative regulation of signal transduction	2	8.09	2.98e-11	4.87e-10	37|247|162|3527	PF00001;PF00002;PF00010;PF00019;PF00028;PF00041;PF00046;PF00049;PF00057;PF00061;PF00079;PF00110;PF00250;PF00320;PF00386;PF00615;PF00683;PF00688;PF00870;PF01153;PF01391;PF01392;PF01833;PF02210;PF02214;PF02460;PF02793;PF03045;PF04706;PF05923;PF07645;PF07679;PF07714;PF10409;PF12444;PF13855;PF13895
Group	GO:1901214	regulation of neuron death	2	9.08	4.14e-11	6.64e-10	20|247|51|3527	PF00001;PF00041;PF00046;PF00048;PF00060;PF00071;PF00167;PF00250;PF00497;PF00520;PF00870;PF01094;PF01392;PF01404;PF03299;PF07679;PF07710;PF07714;PF13855;PF13927
Group	GO:0032880	regulation of protein localization	2	8.59	4.73e-11	7.45e-10	25|247|80|3527	PF00001;PF00019;PF00048;PF00059;PF00061;PF00071;PF00074;PF00110;PF00123;PF00250;PF00320;PF00386;PF00615;PF00622;PF00688;PF01391;PF01392;PF01534;PF02210;PF02758;PF05729;PF07686;PF13516;PF13855;PF13927
Group	GO:0010740	positive regulation of intracellular protein kinase cascade	2	8.66	4.88e-11	7.57e-10	24|247|74|3527	PF00001;PF00010;PF00019;PF00041;PF00048;PF00049;PF00061;PF00100;PF00110;PF00167;PF00320;PF00386;PF00615;PF00688;PF01023;PF01053;PF01391;PF05729;PF07679;PF07714;PF11527;PF13516;PF13895;PF13927
Group	GO:0007548	sex differentiation	2	8.57	6.74e-11	1.03e-09	24|247|75|3527	PF00007;PF00010;PF00019;PF00022;PF00041;PF00046;PF00110;PF00125;PF00167;PF00250;PF00320;PF00688;PF00751;PF00870;PF01085;PF01392;PF01421;PF01534;PF07679;PF07686;PF07714;PF12444;PF13895;PF13927
Group	GO:0034220	ion transmembrane transport	2	8.66	8.96e-11	1.28e-09	22|247|64|3527	PF00027;PF00046;PF00060;PF00089;PF00100;PF00230;PF00497;PF00520;PF00622;PF00858;PF00909;PF01007;PF01094;PF01699;PF02026;PF02214;PF03520;PF06459;PF07686;PF07885;PF08344;PF13426
Group	GO:0010975	regulation of neuron projection development	2	8.66	8.96e-11	1.28e-09	22|247|64|3527	PF00038;PF00041;PF00060;PF00110;PF00135;PF00167;PF00435;PF00497;PF01094;PF01404;PF01562;PF01833;PF01979;PF02931;PF02932;PF07679;PF07714;PF10409;PF13516;PF13855;PF13895;PF13927
Group	GO:0001817	regulation of cytokine production	2	8.43	8.66e-11	1.28e-09	25|247|82|3527	PF00001;PF00019;PF00048;PF00059;PF00061;PF00100;PF00110;PF00250;PF00320;PF00386;PF00560;PF00622;PF00688;PF01273;PF01391;PF01510;PF02758;PF02931;PF02932;PF05729;PF07686;PF13516;PF13855;PF13895;PF13927
Group	GO:0048562	embryonic organ morphogenesis	2	8.90	1.08e-10	1.50e-09	19|247|48|3527	PF00010;PF00028;PF00046;PF00063;PF00089;PF00110;PF00167;PF00250;PF00292;PF00907;PF01392;PF01534;PF02210;PF03299;PF03529;PF07679;PF07714;PF12413;PF12444
Group	GO:0060348	bone development	2	9.01	1.12e-10	1.54e-09	18|247|43|3527	PF00010;PF00019;PF00053;PF00057;PF00245;PF00520;PF00622;PF00688;PF01391;PF02026;PF02210;PF03299;PF06459;PF07645;PF07679;PF07714;PF12444;PF13895
Group	GO:0043069	negative regulation of programmed cell death	2	8.08	1.28e-10	1.73e-09	29|247|110|3527	PF00001;PF00010;PF00019;PF00041;PF00046;PF00048;PF00049;PF00060;PF00071;PF00147;PF00167;PF00230;PF00250;PF00273;PF00292;PF00320;PF00497;PF00520;PF00613;PF00688;PF01053;PF01094;PF01415;PF03299;PF07714;PF12444;PF13855;PF13895;PF13927
Group	GO:0002684	positive regulation of immune system process	2	7.97	1.61e-10	2.14e-09	30|247|118|3527	PF00001;PF00041;PF00048;PF00057;PF00059;PF00084;PF00089;PF00090;PF00100;PF00129;PF00167;PF00250;PF00320;PF00337;PF00386;PF00431;PF00560;PF00930;PF01085;PF01391;PF01415;PF01823;PF02758;PF05729;PF07645;PF07686;PF07714;PF13516;PF13855;PF13895
Group	GO:0002252	immune effector process	2	8.09	2.35e-10	3.00e-09	26|247|92|3527	PF00001;PF00041;PF00048;PF00057;PF00059;PF00071;PF00084;PF00089;PF00090;PF00100;PF00337;PF00386;PF00431;PF00560;PF00870;PF01391;PF01404;PF01823;PF07645;PF07679;PF07686;PF07714;PF10409;PF13855;PF13895;PF13927
Group	GO:0055065	metal ion homeostasis	2	8.09	2.35e-10	3.00e-09	26|247|92|3527	PF00001;PF00002;PF00003;PF00010;PF00041;PF00048;PF00060;PF00067;PF00210;PF00497;PF00503;PF00520;PF00530;PF00622;PF00992;PF01094;PF02026;PF02793;PF02931;PF02932;PF03299;PF06459;PF07562;PF07714;PF07885;PF08344
Group	GO:0007169	transmembrane receptor protein tyrosine kinase signaling pathway	2	8.12	2.73e-10	3.36e-09	25|247|86|3527	PF00019;PF00041;PF00049;PF00051;PF00061;PF00071;PF00147;PF00167;PF00211;PF00250;PF00431;PF00613;PF00688;PF01404;PF02351;PF06327;PF07645;PF07679;PF07686;PF07714;PF10409;PF12444;PF13855;PF13895;PF13927
Group	GO:1900542	regulation of purine nucleotide metabolic process	2	8.12	2.73e-10	3.36e-09	25|247|86|3527	PF00001;PF00002;PF00003;PF00027;PF00041;PF00048;PF00063;PF00071;PF00089;PF00110;PF00123;PF00167;PF00211;PF00503;PF00615;PF00631;PF00992;PF01094;PF01404;PF02736;PF02793;PF06327;PF07562;PF07714;PF13855
Group	GO:0043549	regulation of kinase activity	2	7.75	2.70e-10	3.36e-09	32|247|135|3527	PF00001;PF00019;PF00027;PF00041;PF00048;PF00049;PF00051;PF00071;PF00100;PF00110;PF00167;PF00211;PF00386;PF00615;PF00688;PF01391;PF01392;PF01534;PF01858;PF02210;PF02931;PF02932;PF06327;PF07645;PF07679;PF07714;PF08934;PF11357;PF13516;PF13855;PF13895;PF13927
Group	GO:0008285	negative regulation of cell proliferation	2	7.95	3.26e-10	3.90e-09	27|247|100|3527	PF00010;PF00019;PF00046;PF00061;PF00074;PF00079;PF00089;PF00110;PF00210;PF00250;PF00292;PF00320;PF00386;PF00688;PF00870;PF00907;PF01391;PF03299;PF05923;PF07679;PF07686;PF07710;PF07714;PF10409;PF12444;PF13895;PF13927
Group	GO:0030001	metal ion transport	2	7.67	4.49e-10	5.31e-09	31|247|130|3527	PF00001;PF00027;PF00041;PF00046;PF00048;PF00060;PF00067;PF00089;PF00100;PF00209;PF00230;PF00497;PF00520;PF00622;PF00858;PF01007;PF01094;PF01699;PF01833;PF02026;PF02214;PF02931;PF02932;PF03520;PF06459;PF06512;PF07686;PF07885;PF08344;PF11933;PF13426
Group	GO:0048638	regulation of developmental growth	2	8.18	4.77e-10	5.50e-09	22|247|69|3527	PF00010;PF00019;PF00046;PF00063;PF00100;PF00110;PF00167;PF00320;PF00435;PF00560;PF00622;PF00688;PF00907;PF01392;PF01562;PF02210;PF02736;PF07679;PF07714;PF13855;PF13895;PF13927
Group	GO:0001932	regulation of protein phosphorylation	2	7.46	4.74e-10	5.50e-09	36|247|169|3527	PF00001;PF00010;PF00019;PF00027;PF00041;PF00048;PF00049;PF00051;PF00057;PF00071;PF00100;PF00110;PF00167;PF00211;PF00386;PF00615;PF00688;PF01391;PF01392;PF01534;PF01858;PF02210;PF02931;PF02932;PF06327;PF07645;PF07679;PF07714;PF08934;PF11357;PF11527;PF12444;PF13516;PF13855;PF13895;PF13927
Group	GO:0060541	respiratory system development	2	7.99	5.46e-10	6.22e-09	24|247|82|3527	PF00010;PF00019;PF00028;PF00041;PF00045;PF00049;PF00057;PF00059;PF00100;PF00110;PF00135;PF00167;PF00320;PF00413;PF00435;PF00688;PF01391;PF01471;PF07645;PF07679;PF07714;PF10409;PF13855;PF13895
Group	GO:0035239	tube morphogenesis	2	7.70	6.70e-10	7.55e-09	28|247|110|3527	PF00001;PF00010;PF00019;PF00045;PF00046;PF00049;PF00090;PF00110;PF00167;PF00193;PF00292;PF00320;PF00413;PF00435;PF00520;PF00688;PF00870;PF00907;PF01085;PF01391;PF01392;PF01471;PF01534;PF07679;PF07686;PF07714;PF12444;PF13855
Group	GO:0051130	positive regulation of cellular component organization	2	7.69	8.58e-10	9.44e-09	27|247|104|3527	PF00001;PF00019;PF00022;PF00031;PF00041;PF00046;PF00048;PF00059;PF00071;PF00110;PF00135;PF00167;PF00292;PF00688;PF00870;PF01275;PF01391;PF01404;PF01979;PF02210;PF04505;PF07679;PF07686;PF07710;PF07714;PF13855;PF13895
Group	GO:0040017	positive regulation of locomotion	2	8.18	1.17e-09	1.27e-08	19|247|54|3527	PF00001;PF00007;PF00019;PF00048;PF00053;PF00055;PF00090;PF00100;PF00110;PF00147;PF00167;PF00320;PF00688;PF01562;PF07679;PF07714;PF12444;PF13895;PF13927
Group	GO:0072507	divalent inorganic cation homeostasis	2	7.91	1.20e-09	1.29e-08	22|247|72|3527	PF00001;PF00002;PF00003;PF00041;PF00048;PF00060;PF00497;PF00503;PF00520;PF00622;PF00992;PF01094;PF01699;PF02026;PF02793;PF02931;PF02932;PF03299;PF06459;PF07562;PF07714;PF08344
Group	GO:0048608	reproductive structure development	2	7.44	1.52e-09	1.58e-08	29|247|121|3527	PF00007;PF00010;PF00019;PF00022;PF00041;PF00046;PF00049;PF00071;PF00110;PF00125;PF00147;PF00167;PF00193;PF00250;PF00320;PF00560;PF00688;PF00751;PF00870;PF01421;PF01534;PF07679;PF07686;PF07714;PF12444;PF13516;PF13855;PF13895;PF13927
Group	GO:0034330	cell junction organization	2	7.88	1.73e-09	1.78e-08	21|247|67|3527	PF00019;PF00028;PF00029;PF00041;PF00053;PF00055;PF00071;PF00110;PF00135;PF00435;PF00688;PF00822;PF01049;PF01391;PF02210;PF07645;PF07679;PF07686;PF07714;PF10582;PF13895
Group	GO:0008544	epidermis development	2	7.74	2.15e-09	2.16e-08	22|247|74|3527	PF00010;PF00019;PF00038;PF00063;PF00135;PF00292;PF00520;PF00560;PF00622;PF00688;PF00870;PF01391;PF01392;PF01410;PF01534;PF02026;PF03299;PF06459;PF07679;PF07714;PF12444;PF13855
Group	GO:0031347	regulation of defense response	2	7.49	2.20e-09	2.19e-08	26|247|101|3527	PF00001;PF00031;PF00041;PF00048;PF00059;PF00061;PF00067;PF00079;PF00084;PF00089;PF00100;PF00129;PF00320;PF00386;PF00560;PF01391;PF02758;PF05729;PF07679;PF07686;PF07714;PF13306;PF13516;PF13855;PF13895;PF13927
Group	GO:0050776	regulation of immune response	2	7.35	2.51e-09	2.47e-08	28|247|116|3527	PF00041;PF00057;PF00059;PF00079;PF00084;PF00089;PF00090;PF00100;PF00129;PF00250;PF00320;PF00386;PF00431;PF00560;PF01391;PF01510;PF01823;PF02758;PF02760;PF07645;PF07679;PF07686;PF07714;PF13306;PF13516;PF13855;PF13895;PF13927
Group	GO:0051345	positive regulation of hydrolase activity	2	7.48	2.79e-09	2.72e-08	25|247|95|3527	PF00001;PF00010;PF00019;PF00041;PF00048;PF00063;PF00074;PF00110;PF00167;PF00211;PF00250;PF00503;PF00615;PF00631;PF00688;PF00870;PF00992;PF01404;PF02758;PF05729;PF06327;PF07679;PF07714;PF13516;PF13895
Group	GO:0030855	epithelial cell differentiation	2	7.70	3.17e-09	3.06e-08	21|247|69|3527	PF00010;PF00019;PF00024;PF00038;PF00041;PF00049;PF00100;PF00110;PF00135;PF00250;PF00292;PF00320;PF00688;PF00870;PF01392;PF01534;PF03299;PF07645;PF07679;PF07714;PF13895
Group	GO:0048705	skeletal system morphogenesis	2	7.89	5.59e-09	5.13e-08	17|247|47|3527	PF00010;PF00019;PF00046;PF00053;PF00057;PF00245;PF00688;PF00907;PF01391;PF02210;PF03299;PF07645;PF07679;PF07714;PF12413;PF12444;PF13895
Group	GO:0051272	positive regulation of cellular component movement	2	7.89	5.59e-09	5.13e-08	17|247|47|3527	PF00001;PF00007;PF00019;PF00048;PF00084;PF00090;PF00100;PF00110;PF00147;PF00167;PF00320;PF00688;PF01562;PF07714;PF12444;PF13895;PF13927
Group	GO:0009725	response to hormone stimulus	2	7.02	5.57e-09	5.13e-08	31|247|143|3527	PF00001;PF00002;PF00019;PF00041;PF00045;PF00046;PF00049;PF00061;PF00079;PF00089;PF00167;PF00201;PF00211;PF00230;PF00250;PF00320;PF00386;PF00413;PF00560;PF00613;PF00631;PF00688;PF01391;PF01471;PF02793;PF05729;PF06327;PF07714;PF10409;PF13516;PF13855
Group	GO:0034097	response to cytokine stimulus	2	7.53	5.65e-09	5.14e-08	21|247|71|3527	PF00001;PF00041;PF00048;PF00067;PF00079;PF00129;PF00386;PF00777;PF01391;PF01431;PF01979;PF02758;PF02760;PF03098;PF04505;PF05649;PF05729;PF07679;PF07714;PF13895;PF13927
Group	GO:0003002	regionalization	2	7.02	6.51e-09	5.87e-08	30|247|136|3527	PF00010;PF00019;PF00028;PF00041;PF00046;PF00057;PF00063;PF00110;PF00135;PF00167;PF00250;PF00292;PF00320;PF00560;PF00615;PF00622;PF00688;PF00870;PF01085;PF01153;PF01392;PF01534;PF02460;PF03045;PF03529;PF05923;PF07679;PF07710;PF07714;PF12003
Group	GO:0008284	positive regulation of cell proliferation	2	7.09	7.74e-09	6.72e-08	27|247|114|3527	PF00001;PF00010;PF00019;PF00041;PF00046;PF00048;PF00049;PF00074;PF00089;PF00100;PF00110;PF00167;PF00230;PF00250;PF00292;PF00320;PF00688;PF00870;PF00907;PF00930;PF01085;PF01415;PF07679;PF07686;PF07714;PF12444;PF13895
Group	GO:0051606	detection of stimulus	2	7.55	8.85e-09	7.61e-08	19|247|60|3527	PF00001;PF00003;PF00028;PF00059;PF00060;PF00089;PF00503;PF00520;PF01094;PF01510;PF05729;PF07562;PF07679;PF07714;PF13516;PF13853;PF13855;PF13895;PF13927
Group	GO:0051216	cartilage development	2	7.81	9.95e-09	8.48e-08	16|247|43|3527	PF00010;PF00019;PF00046;PF00053;PF00057;PF00110;PF00167;PF00688;PF01391;PF01410;PF02210;PF07645;PF07679;PF12413;PF12444;PF13895
Group	GO:0016337	cell-cell adhesion	2	7.65	1.17e-08	9.84e-08	17|247|49|3527	PF00028;PF00041;PF00059;PF00110;PF00135;PF00688;PF00822;PF01049;PF02210;PF07679;PF07686;PF07714;PF08266;PF12444;PF13855;PF13895;PF13927
Group	GO:0048511	rhythmic process	2	7.53	1.23e-08	1.03e-07	18|247|55|3527	PF00001;PF00010;PF00019;PF00027;PF00041;PF00061;PF00250;PF00320;PF00520;PF00688;PF01392;PF01421;PF02931;PF02932;PF07679;PF07714;PF13895;PF13927
Group	GO:0045165	cell fate commitment	2	6.97	1.70e-08	1.39e-07	25|247|103|3527	PF00010;PF00019;PF00046;PF00110;PF00147;PF00167;PF00250;PF00292;PF00320;PF00435;PF00688;PF00870;PF00907;PF01085;PF01562;PF02351;PF03299;PF03529;PF07645;PF07679;PF07714;PF10409;PF12444;PF13895;PF13927
Group	GO:0035556	intracellular signal transduction	2	6.56	2.04e-08	1.63e-07	35|247|184|3527	PF00001;PF00010;PF00027;PF00041;PF00046;PF00048;PF00049;PF00060;PF00063;PF00071;PF00100;PF00110;PF00157;PF00167;PF00211;PF00320;PF00435;PF00497;PF00503;PF00520;PF00560;PF00613;PF00870;PF01094;PF05729;PF07645;PF07679;PF07710;PF07714;PF10409;PF12444;PF13516;PF13855;PF13895;PF13927
Group	GO:0050890	cognition	2	7.23	3.17e-08	2.48e-07	18|247|58|3527	PF00057;PF00060;PF00071;PF00089;PF00135;PF00250;PF00351;PF00497;PF00520;PF00530;PF01023;PF01094;PF01699;PF02210;PF02931;PF02932;PF07714;PF10565
Group	GO:0001558	regulation of cell growth	2	7.06	3.36e-08	2.60e-07	20|247|71|3527	PF00019;PF00041;PF00089;PF00110;PF00167;PF00250;PF00431;PF00435;PF00688;PF00870;PF01454;PF01562;PF02210;PF07679;PF07710;PF07714;PF10409;PF13855;PF13895;PF13927
Group	GO:0070848	response to growth factor stimulus	2	7.53	4.48e-08	3.42e-07	14|247|36|3527	PF00048;PF00071;PF00110;PF00167;PF00211;PF00292;PF00320;PF00431;PF06327;PF07679;PF07686;PF07714;PF12444;PF13895
Group	GO:0007186	G-protein coupled receptor signaling pathway	2	7.04	5.74e-08	4.24e-07	18|247|60|3527	PF00001;PF00002;PF00003;PF00057;PF00123;PF00211;PF00503;PF00520;PF00615;PF00631;PF01094;PF02793;PF02931;PF02932;PF06327;PF07562;PF12003;PF13853
Group	GO:0001822	kidney development	2	6.90	5.63e-08	4.24e-07	20|247|73|3527	PF00010;PF00019;PF00041;PF00046;PF00110;PF00147;PF00167;PF00292;PF00320;PF00386;PF00688;PF01391;PF01431;PF03299;PF05649;PF07679;PF07714;PF10162;PF12444;PF13895
Group	GO:0030097	hemopoiesis	2	6.62	5.78e-08	4.24e-07	25|247|109|3527	PF00001;PF00010;PF00019;PF00041;PF00042;PF00046;PF00063;PF00071;PF00110;PF00320;PF00337;PF00688;PF00870;PF01392;PF01534;PF01576;PF02736;PF07645;PF07679;PF07686;PF07710;PF07714;PF13855;PF13895;PF13927
Group	GO:0050865	regulation of cell activation	2	6.82	5.87e-08	4.27e-07	21|247|80|3527	PF00001;PF00010;PF00019;PF00041;PF00048;PF00059;PF00084;PF00100;PF00167;PF00250;PF00320;PF00337;PF00688;PF00930;PF01085;PF01415;PF01510;PF07686;PF07714;PF13895;PF13927
Group	GO:0019216	regulation of lipid metabolic process	2	6.91	6.68e-08	4.68e-07	19|247|67|3527	PF00001;PF00019;PF00041;PF00049;PF00051;PF00061;PF00067;PF00071;PF00100;PF00167;PF00386;PF00688;PF01391;PF01442;PF01858;PF07679;PF07714;PF08934;PF13895
Group	GO:0031589	cell-substrate adhesion	2	7.39	6.76e-08	4.70e-07	14|247|37|3527	PF00041;PF00094;PF00100;PF01391;PF01392;PF01404;PF01534;PF01826;PF07645;PF07686;PF07714;PF08742;PF13895;PF13927
Group	GO:2000027	regulation of organ morphogenesis	2	6.95	7.64e-08	5.20e-07	18|247|61|3527	PF00001;PF00010;PF00019;PF00046;PF00051;PF00089;PF00110;PF00167;PF00292;PF00320;PF00688;PF01392;PF01534;PF03145;PF03299;PF07679;PF07714;PF12444
Group	GO:0090092	regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	2	7.21	8.08e-08	5.46e-07	15|247|43|3527	PF00010;PF00019;PF00046;PF00090;PF00094;PF00100;PF00157;PF00683;PF00688;PF00870;PF01392;PF03045;PF03299;PF07645;PF13516
Group	GO:0046903	secretion	2	6.51	8.49e-08	5.70e-07	25|247|111|3527	PF00001;PF00019;PF00027;PF00041;PF00046;PF00048;PF00063;PF00071;PF00089;PF00123;PF00386;PF00520;PF00683;PF00688;PF02210;PF02736;PF02931;PF02932;PF05835;PF07645;PF07679;PF07714;PF08344;PF13895;PF13927
Group	GO:0045597	positive regulation of cell differentiation	2	6.48	1.29e-07	8.42e-07	23|247|98|3527	PF00001;PF00010;PF00019;PF00041;PF00046;PF00090;PF00110;PF00250;PF00292;PF00320;PF00386;PF00530;PF00688;PF00907;PF01085;PF01391;PF01415;PF07645;PF07679;PF07714;PF12444;PF13855;PF13895
Group	GO:0044092	negative regulation of molecular function	2	6.22	1.42e-07	9.19e-07	29|247|146|3527	PF00001;PF00003;PF00010;PF00028;PF00031;PF00041;PF00046;PF00050;PF00051;PF00067;PF00079;PF00147;PF00250;PF00386;PF00688;PF00992;PF01094;PF01391;PF01534;PF01858;PF02210;PF02758;PF03299;PF05729;PF08266;PF08374;PF08934;PF13516;PF13895
Group	GO:0021700	developmental maturation	2	6.67	1.45e-07	9.32e-07	19|247|70|3527	PF00019;PF00028;PF00041;PF00060;PF00071;PF00435;PF00497;PF00520;PF00560;PF00622;PF00688;PF01094;PF01833;PF02026;PF06459;PF07679;PF13855;PF13895;PF13927
Group	GO:0008015	blood circulation	2	6.81	1.50e-07	9.59e-07	17|247|57|3527	PF00001;PF00010;PF00041;PF00067;PF00079;PF00089;PF00211;PF00386;PF00520;PF00992;PF01094;PF01391;PF02210;PF02736;PF03098;PF03520;PF07679
Group	GO:0006952	defense response	2	6.08	1.58e-07	1.00e-06	33|247|181|3527	PF00001;PF00031;PF00041;PF00048;PF00057;PF00059;PF00071;PF00079;PF00084;PF00089;PF00129;PF00193;PF00560;PF00879;PF01023;PF01094;PF01273;PF01391;PF01404;PF01510;PF01823;PF02758;PF02886;PF04505;PF05729;PF07686;PF07714;PF10409;PF13306;PF13516;PF13855;PF13895;PF13927
Group	GO:0003151	outflow tract morphogenesis	2	7.56	2.35e-07	1.46e-06	10|247|20|3527	PF00010;PF00110;PF00167;PF00520;PF00622;PF00907;PF02026;PF06459;PF07679;PF07714
Group	GO:0009991	response to extracellular stimulus	2	6.19	2.54e-07	1.57e-06	25|247|117|3527	PF00010;PF00019;PF00027;PF00061;PF00067;PF00071;PF00110;PF00123;PF00159;PF00230;PF00273;PF00292;PF00320;PF00503;PF00520;PF00613;PF00622;PF00688;PF00909;PF01392;PF01534;PF02024;PF07714;PF10409;PF12444
Group	GO:0035107	appendage morphogenesis	2	6.31	2.59e-07	1.58e-06	22|247|94|3527	PF00046;PF00057;PF00063;PF00100;PF00110;PF00135;PF00167;PF00292;PF00431;PF00435;PF00503;PF00870;PF00907;PF01085;PF01153;PF01400;PF01833;PF03299;PF07645;PF07679;PF07714;PF13855
Group	GO:0048732	gland development	2	6.31	3.69e-07	2.22e-06	20|247|81|3527	PF00010;PF00041;PF00046;PF00049;PF00123;PF00147;PF00167;PF00193;PF00250;PF00292;PF00870;PF00907;PF01391;PF01562;PF02210;PF07679;PF07686;PF07714;PF10409;PF12444
Group	GO:0014070	response to organic cyclic compound	2	6.73	4.26e-07	2.55e-06	14|247|42|3527	PF00001;PF00048;PF00060;PF00067;PF00201;PF00245;PF00497;PF00520;PF00622;PF01094;PF02026;PF02931;PF02932;PF06459
Group	GO:0043279	response to alkaloid	2	7.08	4.81e-07	2.86e-06	11|247|26|3527	PF00001;PF00060;PF00497;PF00503;PF00520;PF00622;PF01094;PF02026;PF02931;PF02932;PF06459
Group	GO:0045321	leukocyte activation	2	6.07	4.94e-07	2.87e-06	23|247|105|3527	PF00001;PF00010;PF00041;PF00046;PF00048;PF00059;PF00110;PF00129;PF00250;PF00337;PF00613;PF00870;PF01534;PF02192;PF02931;PF02932;PF07679;PF07686;PF07714;PF13516;PF13855;PF13895;PF13927
Group	GO:0070482	response to oxygen levels	2	6.47	5.18e-07	2.99e-06	16|247|55|3527	PF00010;PF00019;PF00042;PF00045;PF00067;PF00074;PF00147;PF00211;PF00230;PF00413;PF00520;PF00530;PF00688;PF01471;PF02931;PF02932
Group	GO:0006909	phagocytosis	2	6.52	5.72e-07	3.28e-06	15|247|49|3527	PF00022;PF00041;PF00053;PF00057;PF00059;PF00084;PF00320;PF01391;PF01562;PF07645;PF07679;PF07686;PF07714;PF13895;PF13927
Group	GO:0016055	Wnt receptor signaling pathway	2	6.61	7.95e-07	4.48e-06	13|247|38|3527	PF00010;PF00049;PF00057;PF00110;PF00167;PF00193;PF00320;PF00435;PF01392;PF01534;PF02736;PF05923;PF07714
Group	GO:0060627	regulation of vesicle-mediated transport	2	6.28	8.87e-07	4.94e-06	16|247|57|3527	PF00001;PF00031;PF00048;PF00059;PF00071;PF00100;PF00386;PF00520;PF01391;PF01833;PF02210;PF02351;PF07645;PF07686;PF07714;PF13895
Group	GO:0030111	regulation of Wnt receptor signaling pathway	2	6.28	8.87e-07	4.94e-06	16|247|57|3527	PF00019;PF00028;PF00041;PF00046;PF00057;PF00110;PF00688;PF01153;PF01391;PF01392;PF04706;PF05923;PF07679;PF07714;PF12444;PF13895
Group	GO:0031099	regeneration	2	7.17	9.77e-07	5.34e-06	9|247|18|3527	PF00038;PF00041;PF00061;PF00089;PF00110;PF00147;PF01442;PF07645;PF13855
Group	GO:0036075	replacement ossification	2	7.17	9.77e-07	5.34e-06	9|247|18|3527	PF00010;PF00019;PF00053;PF00057;PF00245;PF00688;PF02210;PF07679;PF13895
Group	GO:0007444	imaginal disc development	2	6.00	1.13e-06	5.99e-06	19|247|79|3527	PF00028;PF00041;PF00045;PF00046;PF00063;PF00100;PF00135;PF00292;PF00413;PF00431;PF00435;PF01400;PF01471;PF01833;PF07645;PF07679;PF07686;PF07714;PF13855
Group	GO:0010817	regulation of hormone levels	2	6.11	1.20e-06	6.32e-06	17|247|65|3527	PF00001;PF00019;PF00027;PF00046;PF00061;PF00067;PF00201;PF00246;PF00520;PF00560;PF00683;PF00685;PF00688;PF01431;PF03098;PF05649;PF07645
Group	GO:0034762	regulation of transmembrane transport	2	5.94	1.40e-06	7.29e-06	19|247|80|3527	PF00001;PF00019;PF00061;PF00100;PF00135;PF00520;PF00615;PF00622;PF00688;PF00822;PF01391;PF01392;PF01534;PF02026;PF02210;PF06459;PF13516;PF13855;PF13895
Group	GO:0009886	post-embryonic morphogenesis	2	5.85	1.54e-06	7.98e-06	20|247|88|3527	PF00010;PF00045;PF00046;PF00063;PF00100;PF00135;PF00413;PF00431;PF00435;PF00560;PF01400;PF01471;PF01833;PF07645;PF07679;PF07686;PF07714;PF10409;PF13516;PF13855
Group	GO:0030003	cellular cation homeostasis	2	5.70	1.66e-06	8.44e-06	23|247|112|3527	PF00001;PF00002;PF00003;PF00010;PF00041;PF00048;PF00210;PF00503;PF00520;PF00530;PF00622;PF00992;PF01699;PF01813;PF02026;PF02793;PF02931;PF02932;PF06459;PF07562;PF07714;PF07885;PF08344
Group	GO:0015672	monovalent inorganic cation transport	2	6.02	1.89e-06	9.47e-06	16|247|60|3527	PF00027;PF00089;PF00209;PF00230;PF00520;PF00858;PF00909;PF01007;PF01699;PF02214;PF03520;PF06512;PF07686;PF07885;PF11933;PF13426
Group	GO:0044087	regulation of cellular component biogenesis	2	5.69	1.98e-06	9.71e-06	22|247|105|3527	PF00001;PF00022;PF00041;PF00046;PF00048;PF00060;PF00061;PF00063;PF00071;PF00110;PF00135;PF00497;PF00622;PF01094;PF01275;PF01392;PF01404;PF01979;PF02210;PF04505;PF07714;PF10409
Group	GO:0007422	peripheral nervous system development	2	6.36	2.09e-06	1.02e-05	12|247|35|3527	PF00010;PF00019;PF00041;PF00046;PF00135;PF00157;PF01421;PF01562;PF07679;PF08516;PF12444;PF13895
Group	GO:0048678	response to axon injury	2	7.05	2.17e-06	1.04e-05	8|247|15|3527	PF00041;PF00061;PF00147;PF01442;PF01979;PF07645;PF07679;PF13855
Group	GO:0048747	muscle fiber development	2	6.23	2.14e-06	1.04e-05	13|247|41|3527	PF00001;PF00063;PF00147;PF00622;PF01392;PF01576;PF02026;PF02736;PF06459;PF07679;PF07686;PF07714;PF13895
Group	GO:0007519	skeletal muscle tissue development	2	5.93	2.41e-06	1.15e-05	16|247|61|3527	PF00001;PF00010;PF00041;PF00049;PF00147;PF00250;PF00520;PF00622;PF01392;PF01562;PF02026;PF06459;PF07679;PF07686;PF07714;PF13895
Group	GO:0045765	regulation of angiogenesis	2	6.06	2.65e-06	1.25e-05	14|247|48|3527	PF00001;PF00002;PF00041;PF00048;PF00067;PF00071;PF00079;PF00084;PF00090;PF00147;PF00167;PF00230;PF02793;PF07645
Group	GO:0048569	post-embryonic organ development	2	5.67	2.71e-06	1.27e-05	20|247|91|3527	PF00010;PF00045;PF00046;PF00063;PF00100;PF00135;PF00413;PF00431;PF00435;PF00560;PF01400;PF01471;PF01833;PF07645;PF07679;PF07686;PF07714;PF13516;PF13855;PF13895
Group	GO:0007512	adult heart development	2	7.54	2.77e-06	1.29e-05	6|247|8|3527	PF00001;PF00041;PF00063;PF01576;PF02736;PF07679
Group	GO:0007498	mesoderm development	2	6.22	2.94e-06	1.35e-05	12|247|36|3527	PF00001;PF00010;PF00019;PF00046;PF00167;PF00250;PF00435;PF00688;PF00870;PF00907;PF03045;PF13426
Group	GO:0050678	regulation of epithelial cell proliferation	2	5.94	2.95e-06	1.35e-05	15|247|55|3527	PF00010;PF00019;PF00041;PF00046;PF00048;PF00074;PF00079;PF00089;PF00110;PF00167;PF00292;PF00688;PF07679;PF07714;PF12444
Group	GO:0030155	regulation of cell adhesion	2	5.68	3.08e-06	1.40e-05	19|247|84|3527	PF00019;PF00041;PF00048;PF00061;PF00063;PF00110;PF00147;PF00386;PF00688;PF01391;PF01392;PF01404;PF01421;PF01562;PF07645;PF07679;PF07714;PF10409;PF13895
Group	GO:0043408	regulation of MAPK cascade	2	5.68	3.08e-06	1.40e-05	19|247|84|3527	PF00001;PF00010;PF00048;PF00049;PF00071;PF00110;PF00386;PF00615;PF01391;PF01392;PF01404;PF01534;PF05729;PF07679;PF07714;PF13516;PF13855;PF13895;PF13927
Group	GO:0071702	organic substance transport	2	5.45	3.68e-06	1.67e-05	23|247|117|3527	PF00001;PF00019;PF00049;PF00057;PF00061;PF00068;PF00151;PF00209;PF00230;PF00474;PF00497;PF00520;PF00688;PF00909;PF01347;PF01442;PF01740;PF01758;PF02460;PF03024;PF03137;PF03765;PF07714
Group	GO:0002697	regulation of immune effector process	2	5.77	3.83e-06	1.72e-05	16|247|63|3527	PF00001;PF00041;PF00059;PF00084;PF00100;PF00129;PF00250;PF00560;PF01510;PF07686;PF07714;PF13306;PF13516;PF13855;PF13895;PF13927
Group	GO:0050808	synapse organization	2	6.00	3.91e-06	1.74e-05	13|247|43|3527	PF00001;PF00028;PF00063;PF00110;PF00135;PF00147;PF00520;PF01275;PF01392;PF02210;PF07679;PF07714;PF08266
Group	GO:0060173	limb development	2	6.00	3.91e-06	1.74e-05	13|247|43|3527	PF00010;PF00019;PF00046;PF00057;PF00110;PF00167;PF00503;PF00688;PF00870;PF00907;PF03299;PF07679;PF07714
Group	GO:0072657	protein localization to membrane	2	6.09	4.09e-06	1.80e-05	12|247|37|3527	PF00050;PF00053;PF00071;PF00135;PF00167;PF00386;PF00520;PF01391;PF01392;PF02210;PF07679;PF07714
Group	GO:0045596	negative regulation of cell differentiation	2	5.41	4.29e-06	1.87e-05	23|247|118|3527	PF00010;PF00019;PF00046;PF00048;PF00071;PF00089;PF00110;PF00167;PF00292;PF00320;PF00386;PF00688;PF00870;PF00907;PF01085;PF01391;PF01404;PF01510;PF01534;PF07645;PF07679;PF12444;PF13895
Group	GO:0006461	protein complex assembly	2	5.21	4.39e-06	1.91e-05	30|247|180|3527	PF00019;PF00041;PF00042;PF00063;PF00074;PF00094;PF00125;PF00135;PF00167;PF00209;PF00274;PF00386;PF00431;PF00520;PF00613;PF00615;PF00622;PF00688;PF00876;PF01391;PF01576;PF01826;PF01979;PF02214;PF02736;PF07645;PF07679;PF07714;PF08742;PF12444
Group	GO:0008283	cell proliferation	2	5.26	5.08e-06	2.18e-05	26|247|145|3527	PF00001;PF00010;PF00019;PF00027;PF00041;PF00046;PF00051;PF00110;PF00167;PF00292;PF00530;PF00688;PF00870;PF00907;PF01085;PF01153;PF01392;PF01404;PF01534;PF07679;PF07686;PF07710;PF07714;PF10409;PF12444;PF13895
Group	GO:0009799	specification of symmetry	2	5.76	5.86e-06	2.51e-05	14|247|51|3527	PF00010;PF00019;PF00046;PF00110;PF00167;PF00250;PF00560;PF00688;PF00907;PF01085;PF01392;PF01534;PF03045;PF07645
Group	GO:0032535	regulation of cellular component size	2	5.62	5.96e-06	2.54e-05	16|247|65|3527	PF00022;PF00041;PF00046;PF00048;PF00071;PF00110;PF00167;PF00435;PF01562;PF02210;PF07679;PF07714;PF10409;PF13855;PF13895;PF13927
Group	GO:0007568	aging	2	5.67	6.08e-06	2.58e-05	15|247|58|3527	PF00002;PF00010;PF00027;PF00040;PF00059;PF00061;PF00135;PF00250;PF00520;PF00613;PF00870;PF00907;PF01431;PF05649;PF07710
Group	GO:0002165	instar larval or pupal development	2	5.43	7.39e-06	3.08e-05	18|247|81|3527	PF00045;PF00046;PF00063;PF00067;PF00100;PF00135;PF00413;PF00431;PF00435;PF01400;PF01471;PF01833;PF07645;PF07679;PF07686;PF07714;PF10409;PF13855
Group	GO:0007552	metamorphosis	2	5.44	8.31e-06	3.36e-05	17|247|74|3527	PF00045;PF00046;PF00063;PF00100;PF00135;PF00413;PF00431;PF00435;PF01400;PF01471;PF01833;PF07645;PF07679;PF07686;PF07714;PF10409;PF13855
Group	GO:0006508	proteolysis	2	4.95	1.15e-05	4.53e-05	29|247|179|3527	PF00022;PF00040;PF00045;PF00051;PF00057;PF00063;PF00089;PF00090;PF00246;PF00413;PF00431;PF00530;PF00622;PF01390;PF01400;PF01421;PF01431;PF01471;PF01562;PF01576;PF02214;PF02244;PF02736;PF03145;PF04300;PF05649;PF05986;PF08516;PF13516
Group	GO:0008038	neuron recognition	2	6.06	1.20e-05	4.69e-05	9|247|23|3527	PF00041;PF00431;PF00435;PF01400;PF01404;PF07679;PF07714;PF13895;PF13927
Group	GO:0010942	positive regulation of cell death	2	5.09	1.29e-05	4.96e-05	22|247|117|3527	PF00010;PF00019;PF00041;PF00046;PF00048;PF00060;PF00090;PF00386;PF00497;PF00688;PF00870;PF00907;PF01094;PF01391;PF01392;PF01404;PF01442;PF02758;PF03299;PF07679;PF07710;PF10409
Group	GO:0072511	divalent inorganic cation transport	2	5.32	1.36e-05	5.22e-05	16|247|69|3527	PF00001;PF00041;PF00048;PF00060;PF00230;PF00497;PF00520;PF00622;PF01094;PF01699;PF01833;PF02026;PF02931;PF02932;PF06459;PF08344
Group	GO:0007178	transmembrane receptor protein serine/threonine kinase signaling pathway	2	5.40	2.31e-05	8.15e-05	12|247|43|3527	PF00010;PF00019;PF00046;PF00100;PF00110;PF00167;PF00320;PF00683;PF00688;PF00870;PF02736;PF07645
Group	GO:0007411	axon guidance	2	5.05	2.51e-05	8.65e-05	17|247|80|3527	PF00041;PF00046;PF00292;PF00431;PF00435;PF01391;PF01400;PF01404;PF01410;PF01833;PF02210;PF07645;PF07679;PF07714;PF08344;PF13855;PF13895
Group	GO:0051051	negative regulation of transport	2	5.00	4.44e-05	1.46e-04	14|247|60|3527	PF00001;PF00003;PF00019;PF00061;PF00250;PF00386;PF00503;PF00622;PF00688;PF01391;PF01833;PF02898;PF13895;PF13927
Group	GO:0045926	negative regulation of growth	2	5.10	4.85e-05	1.58e-04	12|247|46|3527	PF00019;PF00110;PF00167;PF00250;PF00431;PF00622;PF00688;PF00870;PF01454;PF02210;PF07710;PF10409
Group	GO:0061326	renal tubule development	2	5.27	5.20e-05	1.68e-04	10|247|33|3527	PF00010;PF00046;PF00110;PF00292;PF00907;PF03299;PF07679;PF07686;PF07714;PF12444
Group	GO:0008360	regulation of cell shape	2	4.92	5.40e-05	1.74e-04	14|247|61|3527	PF00024;PF00048;PF00063;PF00071;PF00100;PF00503;PF01576;PF02736;PF07679;PF07686;PF07714;PF10409;PF13895;PF13927
Group	GO:0043269	regulation of ion transport	2	4.70	6.70e-05	2.15e-04	17|247|86|3527	PF00001;PF00048;PF00100;PF00135;PF00435;PF00503;PF00520;PF00622;PF00822;PF00930;PF02026;PF02210;PF02898;PF06459;PF13426;PF13895;PF13927
Group	GO:0080135	regulation of cellular response to stress	2	4.70	6.70e-05	2.15e-04	17|247|86|3527	PF00010;PF00040;PF00041;PF00049;PF00059;PF00071;PF00110;PF00167;PF00560;PF00615;PF01392;PF01404;PF01534;PF05729;PF07714;PF13516;PF13855
Group	GO:0048610	cellular process involved in reproduction	2	4.37	7.36e-05	2.30e-04	29|247|197|3527	PF00001;PF00010;PF00019;PF00028;PF00041;PF00063;PF00071;PF00084;PF00089;PF00100;PF00135;PF00147;PF00320;PF00435;PF00560;PF00622;PF00688;PF00870;PF01085;PF01562;PF02460;PF02931;PF02932;PF07679;PF07686;PF07714;PF11357;PF12444;PF13895
Group	GO:0072347	response to anesthetic	2	6.16	7.61e-05	2.34e-04	5|247|8|3527	PF00053;PF00057;PF02210;PF07679;PF13895
Group	GO:0045199	maintenance of epithelial cell apical/basal polarity	2	6.16	7.61e-05	2.34e-04	5|247|8|3527	PF00053;PF00057;PF02210;PF07679;PF13895
Group	GO:0009416	response to light stimulus	2	4.50	8.10e-05	2.45e-04	21|247|122|3527	PF00001;PF00010;PF00057;PF00060;PF00201;PF00230;PF00250;PF00497;PF00503;PF00520;PF00560;PF00615;PF00870;PF01094;PF01431;PF02931;PF02932;PF05649;PF07710;PF13426;PF13855
Group	GO:0045786	negative regulation of cell cycle	2	4.79	8.84e-05	2.65e-04	13|247|56|3527	PF00019;PF00048;PF00320;PF00688;PF00870;PF01823;PF01858;PF02351;PF07645;PF07679;PF07710;PF07714;PF10409
Group	GO:0007369	gastrulation	2	4.79	8.84e-05	2.65e-04	13|247|56|3527	PF00001;PF00010;PF00019;PF00046;PF00110;PF00167;PF00250;PF00320;PF00435;PF00688;PF00907;PF01049;PF03529
Group	GO:0007009	plasma membrane organization	2	4.91	1.18e-04	3.44e-04	10|247|36|3527	PF00063;PF00071;PF00167;PF00386;PF00435;PF00622;PF01391;PF01576;PF02210;PF02736
Group	GO:0048872	homeostasis of number of cells	2	4.66	1.44e-04	4.05e-04	12|247|51|3527	PF00001;PF00010;PF00019;PF00042;PF00250;PF00320;PF00613;PF00688;PF02192;PF07714;PF12444;PF13927
Group	GO:0060560	developmental growth involved in morphogenesis	2	4.49	1.88e-04	4.96e-04	13|247|60|3527	PF00019;PF00041;PF00057;PF00071;PF00167;PF00560;PF00688;PF01391;PF07679;PF07714;PF12444;PF13855;PF13895
Group	GO:0045893	positive regulation of transcription, DNA-dependent	2	4.16	1.88e-04	4.96e-04	23|247|148|3527	PF00010;PF00019;PF00038;PF00046;PF00100;PF00110;PF00157;PF00167;PF00250;PF00292;PF00320;PF00435;PF00688;PF00870;PF00907;PF01833;PF03299;PF03529;PF07645;PF07714;PF08214;PF12157;PF12444
Group	GO:0016319	mushroom body development	2	5.27	2.07e-04	5.39e-04	6|247|14|3527	PF00041;PF00435;PF01404;PF07679;PF13895;PF13927
Group	GO:0042063	gliogenesis	2	4.49	2.14e-04	5.55e-04	12|247|53|3527	PF00010;PF00046;PF00048;PF00049;PF00167;PF00292;PF01421;PF01562;PF07679;PF08516;PF12444;PF13895
Group	GO:0009100	glycoprotein metabolic process	2	4.27	2.32e-04	6.03e-04	16|247|86|3527	PF00049;PF00094;PF00685;PF00777;PF01390;PF01431;PF01531;PF01762;PF01841;PF02210;PF03567;PF04300;PF04922;PF05649;PF12529;PF13855
Group	GO:0009617	response to bacterium	2	4.22	2.43e-04	6.28e-04	17|247|95|3527	PF00001;PF00048;PF00059;PF00074;PF00079;PF00084;PF00089;PF00129;PF00560;PF00879;PF01273;PF01510;PF02898;PF05729;PF13516;PF13855;PF13895
Group	GO:0032844	regulation of homeostatic process	2	4.30	2.62e-04	6.73e-04	14|247|70|3527	PF00001;PF00010;PF00019;PF00041;PF00048;PF00057;PF00061;PF00089;PF00520;PF00622;PF00688;PF02026;PF06459;PF07714
Group	GO:0023061	signal release	2	4.35	2.66e-04	6.81e-04	13|247|62|3527	PF00001;PF00019;PF00027;PF00046;PF00063;PF00071;PF00520;PF00683;PF00688;PF02210;PF05835;PF07645;PF07714
Group	GO:0032970	regulation of actin filament-based process	2	4.34	3.10e-04	7.45e-04	12|247|55|3527	PF00001;PF00022;PF00041;PF00046;PF00048;PF00071;PF00110;PF01404;PF07686;PF07714;PF13895;PF13927
Group	GO:0018193	peptidyl-amino acid modification	2	3.98	3.12e-04	7.45e-04	23|247|153|3527	PF00001;PF00010;PF00022;PF00041;PF00071;PF00089;PF00246;PF00538;PF00615;PF00777;PF01053;PF01404;PF01442;PF02210;PF02898;PF07645;PF07679;PF07714;PF08214;PF12157;PF13855;PF13895;PF13927
Group	GO:0006357	regulation of transcription from RNA polymerase II promoter	2	3.94	3.20e-04	7.45e-04	25|247|173|3527	PF00010;PF00019;PF00038;PF00042;PF00046;PF00049;PF00157;PF00167;PF00292;PF00320;PF00435;PF00688;PF00751;PF00870;PF00907;PF01833;PF01858;PF03299;PF07645;PF07679;PF07710;PF07714;PF08214;PF12157;PF12444
Group	GO:0016331	morphogenesis of embryonic epithelium	2	4.21	3.70e-04	8.07e-04	13|247|64|3527	PF00046;PF00063;PF00071;PF00110;PF00167;PF00292;PF00320;PF00870;PF01392;PF03299;PF07679;PF07714;PF12444
Group	GO:0051090	regulation of sequence-specific DNA binding transcription factor activity	2	4.21	3.70e-04	8.07e-04	13|247|64|3527	PF00010;PF00067;PF00110;PF00250;PF01053;PF01392;PF01534;PF02758;PF05729;PF07714;PF13516;PF13855;PF13895
Group	GO:0006468	protein phosphorylation	2	3.93	3.95e-04	8.52e-04	21|247|136|3527	PF00001;PF00019;PF00027;PF00041;PF00048;PF00049;PF00063;PF00110;PF00167;PF00615;PF00688;PF01404;PF07645;PF07679;PF07714;PF12444;PF13426;PF13516;PF13855;PF13895;PF13927
Group	GO:0006898	receptor-mediated endocytosis	2	4.49	4.69e-04	1.01e-03	8|247|28|3527	PF00001;PF00040;PF00057;PF00059;PF00135;PF00431;PF00615;PF07645
Group	GO:0051235	maintenance of location	2	4.36	4.92e-04	1.03e-03	9|247|35|3527	PF00210;PF00273;PF00435;PF00683;PF03045;PF07645;PF07714;PF11527;PF12756
Group	GO:0052547	regulation of peptidase activity	2	4.06	4.79e-04	1.03e-03	14|247|74|3527	PF00001;PF00010;PF00031;PF00050;PF00079;PF00090;PF00250;PF00870;PF02210;PF02758;PF03299;PF05729;PF07714;PF13516
Group	GO:0032409	regulation of transporter activity	2	4.11	7.00e-04	1.39e-03	10|247|44|3527	PF00001;PF00100;PF00135;PF00520;PF00622;PF00822;PF02026;PF02210;PF06459;PF13895
Group	GO:0009798	axis specification	2	4.03	7.30e-04	1.44e-03	11|247|52|3527	PF00046;PF00057;PF00063;PF00110;PF00250;PF00292;PF00560;PF00615;PF00622;PF03529;PF07714
Group	GO:0001738	morphogenesis of a polarized epithelium	2	4.24	7.81e-04	1.53e-03	8|247|30|3527	PF00028;PF00053;PF00063;PF00110;PF00870;PF01049;PF01534;PF02210
Group	GO:0051056	regulation of small GTPase mediated signal transduction	2	3.89	7.94e-04	1.55e-03	13|247|69|3527	PF00001;PF00041;PF00048;PF00063;PF00071;PF00110;PF00560;PF01404;PF01833;PF02214;PF07679;PF07714;PF13855
Group	GO:0071496	cellular response to external stimulus	2	3.67	1.23e-03	2.30e-03	14|247|81|3527	PF00019;PF00067;PF00110;PF00230;PF00273;PF00292;PF00320;PF00688;PF00909;PF01392;PF01534;PF07714;PF12444;PF13855
Group	GO:0016358	dendrite development	2	3.70	1.70e-03	2.94e-03	10|247|49|3527	PF00024;PF00041;PF00046;PF00053;PF00292;PF00435;PF00520;PF01404;PF07679;PF07714
Group	GO:0048737	imaginal disc-derived appendage development	2	3.53	2.18e-03	3.72e-03	11|247|59|3527	PF00046;PF00063;PF00100;PF00135;PF00292;PF00431;PF00435;PF01400;PF01833;PF07645;PF13855
Group	GO:0048706	embryonic skeletal system development	2	3.88	2.46e-03	4.11e-03	6|247|21|3527	PF00046;PF00053;PF00907;PF01085;PF02210;PF03299
Group	GO:0007283	spermatogenesis	2	3.38	2.57e-03	4.27e-03	13|247|78|3527	PF00041;PF00063;PF00211;PF00320;PF00538;PF01421;PF01562;PF07679;PF07714;PF08516;PF12444;PF13895;PF13927
Group	GO:0045927	positive regulation of growth	2	3.40	2.88e-03	4.74e-03	11|247|61|3527	PF00010;PF00038;PF00046;PF00063;PF00089;PF00100;PF00125;PF00167;PF00876;PF02460;PF13895
Group	GO:0060638	mesenchymal-epithelial cell signaling	2	4.65	3.05e-03	4.90e-03	3|247|5|3527	PF00041;PF00147;PF07714
Group	GO:0021551	central nervous system morphogenesis	2	4.65	3.05e-03	4.90e-03	3|247|5|3527	PF00041;PF07679;PF13895
Group	GO:0006066	alcohol metabolic process	2	3.22	3.45e-03	5.50e-03	14|247|90|3527	PF00001;PF00019;PF00027;PF00057;PF00061;PF00067;PF00135;PF00320;PF00351;PF00688;PF01442;PF03765;PF04916;PF07645
Group	GO:0007015	actin filament organization	2	3.28	3.74e-03	5.80e-03	11|247|63|3527	PF00001;PF00022;PF00028;PF00046;PF00063;PF00071;PF00074;PF00613;PF01979;PF02214;PF10409
Group	GO:0012501	programmed cell death	2	2.97	4.87e-03	7.54e-03	19|247|144|3527	PF00001;PF00007;PF00010;PF00027;PF00046;PF00090;PF00167;PF00250;PF00870;PF01049;PF01404;PF02758;PF03145;PF03299;PF05729;PF07710;PF10409;PF13516;PF13855
Group	GO:0030031	cell projection assembly	2	3.14	5.43e-03	8.13e-03	10|247|57|3527	PF00028;PF00041;PF00063;PF00071;PF01833;PF02736;PF07714;PF10162;PF13895;PF13927
Group	GO:0031329	regulation of cellular catabolic process	2	2.95	5.70e-03	8.44e-03	16|247|115|3527	PF00001;PF00010;PF00027;PF00041;PF00048;PF00063;PF00071;PF00110;PF00167;PF00615;PF00631;PF00992;PF01404;PF02736;PF07714;PF13855
Group	GO:0031348	negative regulation of defense response	3	9.89	8.83e-11	1.28e-09	13|247|21|3527	PF00001;PF00041;PF00067;PF00079;PF00320;PF00386;PF00560;PF01391;PF07679;PF07714;PF13516;PF13895;PF13927
Group	GO:0032102	negative regulation of response to external stimulus	3	9.31	8.18e-10	9.10e-09	12|247|20|3527	PF00001;PF00041;PF00060;PF00067;PF00110;PF00320;PF00386;PF00497;PF01094;PF01391;PF02024;PF07679
Group	GO:0050714	positive regulation of protein secretion	3	9.34	1.36e-09	1.45e-08	11|247|17|3527	PF00001;PF00019;PF00048;PF00059;PF00074;PF00320;PF00688;PF02758;PF05729;PF07686;PF13516
Group	GO:0045834	positive regulation of lipid metabolic process	3	8.74	1.43e-09	1.50e-08	14|247|29|3527	PF00019;PF00041;PF00049;PF00061;PF00071;PF00100;PF00167;PF00386;PF00688;PF01391;PF01442;PF07679;PF07714;PF13895
Group	GO:0051588	regulation of neurotransmitter transport	3	9.46	1.86e-09	1.89e-08	10|247|14|3527	PF00001;PF00003;PF00019;PF00071;PF00520;PF01094;PF01833;PF02214;PF02931;PF02932
Group	GO:0042472	inner ear morphogenesis	3	8.62	3.28e-09	3.13e-08	13|247|26|3527	PF00028;PF00063;PF00089;PF00167;PF00292;PF00907;PF01392;PF01534;PF03299;PF03529;PF07679;PF07714;PF12444
Group	GO:0050806	positive regulation of synaptic transmission	3	9.64	4.40e-09	4.16e-08	8|247|9|3527	PF00135;PF01094;PF01699;PF02210;PF03736;PF07679;PF10613;PF13855
Group	GO:0021536	diencephalon development	3	8.71	7.33e-09	6.42e-08	11|247|19|3527	PF00019;PF00046;PF00110;PF00123;PF00167;PF00250;PF00292;PF00688;PF07679;PF07714;PF13895
Group	GO:0001657	ureteric bud development	3	8.71	7.33e-09	6.42e-08	11|247|19|3527	PF00010;PF00019;PF00046;PF00110;PF00167;PF00193;PF00292;PF00320;PF00688;PF07679;PF07714
Group	GO:0009636	response to toxin	3	8.71	7.33e-09	6.42e-08	11|247|19|3527	PF00003;PF00048;PF00060;PF00067;PF00135;PF01094;PF02931;PF02932;PF06512;PF07562;PF11933
Group	GO:0006956	complement activation	3	8.43	1.53e-08	1.26e-07	11|247|20|3527	PF00057;PF00059;PF00084;PF00089;PF00090;PF00386;PF00431;PF01391;PF01823;PF07645;PF07686
Group	GO:0030817	regulation of cAMP biosynthetic process	3	8.43	1.53e-08	1.26e-07	11|247|20|3527	PF00001;PF00002;PF00003;PF00089;PF00123;PF00211;PF00503;PF01094;PF02793;PF06327;PF07562
Group	GO:0055024	regulation of cardiac muscle tissue development	3	8.81	1.96e-08	1.59e-07	9|247|13|3527	PF00019;PF00110;PF00167;PF00320;PF00688;PF00907;PF07679;PF07714;PF13895
Group	GO:0050974	detection of mechanical stimulus involved in sensory perception	3	9.06	2.07e-08	1.63e-07	8|247|10|3527	PF00028;PF00089;PF00520;PF01094;PF07679;PF07714;PF13895;PF13927
Group	GO:0071774	response to fibroblast growth factor stimulus	3	9.06	2.07e-08	1.63e-07	8|247|10|3527	PF00048;PF00071;PF00167;PF00211;PF06327;PF07679;PF07714;PF13895
Group	GO:0001816	cytokine production	3	7.85	4.28e-08	3.29e-07	12|247|26|3527	PF00001;PF00040;PF00059;PF00110;PF01833;PF02758;PF05729;PF07679;PF07714;PF13516;PF13895;PF13927
Group	GO:0031128	developmental induction	3	8.93	5.74e-08	4.24e-07	7|247|8|3527	PF00019;PF00046;PF00110;PF00167;PF00688;PF07714;PF12444
Group	GO:0033273	response to vitamin	3	7.93	5.65e-08	4.24e-07	11|247|22|3527	PF00010;PF00019;PF00061;PF00110;PF00230;PF00292;PF00688;PF01392;PF01534;PF07714;PF12444
Group	GO:0032680	regulation of tumor necrosis factor production	3	8.09	6.31e-08	4.45e-07	10|247|18|3527	PF00001;PF00048;PF00386;PF00560;PF01273;PF01391;PF02931;PF02932;PF13516;PF13855
Group	GO:0051339	regulation of lyase activity	3	8.09	6.31e-08	4.45e-07	10|247|18|3527	PF00001;PF00002;PF00003;PF00089;PF00123;PF00211;PF00503;PF01094;PF02793;PF06327
Group	GO:0031279	regulation of cyclase activity	3	8.09	6.31e-08	4.45e-07	10|247|18|3527	PF00001;PF00002;PF00003;PF00089;PF00123;PF00211;PF00503;PF01094;PF02793;PF06327
Group	GO:0022405	hair cycle process	3	8.09	6.31e-08	4.45e-07	10|247|18|3527	PF00019;PF00688;PF00870;PF01391;PF01392;PF01534;PF02210;PF07679;PF07714;PF12444
Group	GO:0031214	biomineral tissue development	3	8.55	7.12e-08	4.92e-07	8|247|11|3527	PF00019;PF00059;PF00110;PF00688;PF00907;PF07679;PF07714;PF13516
Group	GO:0007601	visual perception	3	7.65	7.23e-08	4.96e-07	12|247|27|3527	PF00027;PF00030;PF00046;PF00053;PF00055;PF00063;PF00503;PF00520;PF00615;PF02931;PF02932;PF13385
Group	GO:0030336	negative regulation of cell migration	3	7.70	1.02e-07	6.78e-07	11|247|23|3527	PF00001;PF00019;PF00061;PF00110;PF00386;PF00688;PF00907;PF01391;PF01979;PF10409;PF13855
Group	GO:0002027	regulation of heart rate	3	8.93	1.11e-07	7.32e-07	6|247|6|3527	PF00001;PF00063;PF00520;PF02736;PF03520;PF06512
Group	GO:0030810	positive regulation of nucleotide biosynthetic process	3	8.11	2.01e-07	1.26e-06	8|247|12|3527	PF00001;PF00002;PF00089;PF00123;PF00211;PF00503;PF02793;PF06327
Group	GO:0090102	cochlea development	3	8.11	2.01e-07	1.26e-06	8|247|12|3527	PF00089;PF00292;PF00907;PF01392;PF07679;PF07714;PF12444;PF13895
Group	GO:0043551	regulation of phosphatidylinositol 3-kinase activity	3	7.74	2.60e-07	1.58e-06	9|247|16|3527	PF00019;PF00041;PF00049;PF00051;PF00071;PF00688;PF07679;PF07714;PF13895
Group	GO:0010464	regulation of mesenchymal cell proliferation	3	7.74	2.60e-07	1.58e-06	9|247|16|3527	PF00019;PF00110;PF00250;PF00688;PF00870;PF01085;PF07679;PF07714;PF12444
Group	GO:0002573	myeloid leukocyte differentiation	3	7.72	4.90e-07	2.86e-06	8|247|13|3527	PF00010;PF00063;PF01576;PF02736;PF07679;PF07714;PF13895;PF13927
Group	GO:0050764	regulation of phagocytosis	3	7.72	4.90e-07	2.86e-06	8|247|13|3527	PF00031;PF00059;PF00386;PF01391;PF02210;PF07686;PF07714;PF13895
Group	GO:0051952	regulation of amine transport	3	7.72	4.90e-07	2.86e-06	8|247|13|3527	PF00001;PF00019;PF00027;PF00520;PF01094;PF02931;PF02932;PF10613
Group	GO:0034446	substrate adhesion-dependent cell spreading	3	7.82	7.61e-07	4.31e-06	7|247|10|3527	PF00041;PF01392;PF01404;PF01534;PF07714;PF13895;PF13927
Group	GO:0007224	smoothened signaling pathway	3	7.17	9.77e-07	5.34e-06	9|247|18|3527	PF00010;PF00041;PF00046;PF00292;PF01085;PF01534;PF02460;PF07679;PF13895
Group	GO:0043491	protein kinase B signaling cascade	3	7.36	1.08e-06	5.75e-06	8|247|14|3527	PF00041;PF00046;PF00048;PF07679;PF10409;PF12444;PF13895;PF13927
Group	GO:0072210	metanephric nephron development	3	7.36	1.08e-06	5.75e-06	8|247|14|3527	PF00010;PF00019;PF00292;PF00688;PF07679;PF07714;PF12444;PF13895
Group	GO:0060420	regulation of heart growth	3	7.36	1.08e-06	5.75e-06	8|247|14|3527	PF00110;PF00167;PF00320;PF00907;PF02736;PF07679;PF07714;PF13895
Group	GO:1901216	positive regulation of neuron death	3	7.36	1.08e-06	5.75e-06	8|247|14|3527	PF00041;PF00048;PF00870;PF01392;PF01404;PF03299;PF07679;PF07710
Group	GO:0001666	response to hypoxia	3	6.38	1.11e-06	5.90e-06	14|247|45|3527	PF00010;PF00019;PF00042;PF00045;PF00067;PF00074;PF00230;PF00413;PF00520;PF00530;PF00688;PF01471;PF02931;PF02932
Group	GO:0045161	neuronal ion channel clustering	3	8.15	1.62e-06	8.29e-06	5|247|5|3527	PF00041;PF00435;PF07679;PF13895;PF13927
Group	GO:0060191	regulation of lipase activity	3	6.91	1.74e-06	8.77e-06	9|247|19|3527	PF00001;PF00074;PF00147;PF00211;PF00503;PF06327;PF07679;PF07714;PF13895
Group	GO:0001818	negative regulation of cytokine production	3	6.91	1.74e-06	8.77e-06	9|247|19|3527	PF00001;PF00061;PF00110;PF00250;PF00386;PF01391;PF01510;PF02931;PF02932
Group	GO:0019233	sensory perception of pain	3	7.37	1.97e-06	9.70e-06	7|247|11|3527	PF00001;PF00060;PF00497;PF01094;PF01431;PF02931;PF05649
Group	GO:0030816	positive regulation of cAMP metabolic process	3	7.37	1.97e-06	9.70e-06	7|247|11|3527	PF00001;PF00002;PF00089;PF00123;PF00211;PF02793;PF06327
Group	GO:0050805	negative regulation of synaptic transmission	3	7.37	1.97e-06	9.70e-06	7|247|11|3527	PF00001;PF00060;PF00386;PF01094;PF01391;PF01699;PF10613
Group	GO:0050777	negative regulation of immune response	3	7.05	2.17e-06	1.04e-05	8|247|15|3527	PF00041;PF00079;PF00084;PF00250;PF07679;PF07714;PF13895;PF13927
Group	GO:0050886	endocrine process	3	7.54	2.77e-06	1.29e-05	6|247|8|3527	PF00001;PF00019;PF00079;PF00089;PF00688;PF01392
Group	GO:0030335	positive regulation of cell migration	3	6.22	2.94e-06	1.35e-05	12|247|36|3527	PF00001;PF00019;PF00048;PF00100;PF00110;PF00167;PF00320;PF00688;PF01562;PF07714;PF12444;PF13927
Group	GO:0002088	lens development in camera-type eye	3	6.75	4.07e-06	1.80e-05	8|247|16|3527	PF00030;PF00038;PF00046;PF00110;PF00292;PF07679;PF07714;PF13895
Group	GO:0070167	regulation of biomineral tissue development	3	6.75	4.07e-06	1.80e-05	8|247|16|3527	PF00019;PF00031;PF00110;PF00688;PF02210;PF03299;PF07645;PF12444
Group	GO:0072012	glomerulus vasculature development	3	6.98	4.44e-06	1.92e-05	7|247|12|3527	PF00010;PF00019;PF00147;PF00688;PF07679;PF07714;PF13895
Group	GO:0042593	glucose homeostasis	3	6.14	6.90e-06	2.91e-05	10|247|27|3527	PF00010;PF00046;PF00067;PF00250;PF00292;PF00386;PF00520;PF01391;PF03299;PF13895
Group	GO:0048015	phosphatidylinositol-mediated signaling	3	6.49	7.23e-06	3.03e-05	8|247|17|3527	PF00001;PF00100;PF00320;PF00613;PF07679;PF07714;PF13895;PF13927
Group	GO:0050707	regulation of cytokine secretion	3	6.49	7.23e-06	3.03e-05	8|247|17|3527	PF00001;PF00048;PF00059;PF00250;PF00320;PF02758;PF05729;PF13516
Group	GO:0001964	startle response	3	7.02	7.81e-06	3.17e-05	6|247|9|3527	PF00028;PF00060;PF00497;PF01094;PF02931;PF02932
Group	GO:0003401	axis elongation	3	7.02	7.81e-06	3.17e-05	6|247|9|3527	PF00019;PF00167;PF00688;PF07679;PF07714;PF12444
Group	GO:0048286	lung alveolus development	3	7.02	7.81e-06	3.17e-05	6|247|9|3527	PF00010;PF00049;PF00059;PF07679;PF07714;PF13895
Group	GO:0035162	embryonic hemopoiesis	3	7.02	7.81e-06	3.17e-05	6|247|9|3527	PF00071;PF00320;PF07679;PF07686;PF07714;PF13927
Group	GO:0060004	reflex	3	7.02	7.81e-06	3.17e-05	6|247|9|3527	PF00027;PF00028;PF00089;PF00520;PF02931;PF02932
Group	GO:0007606	sensory perception of chemical stimulus	3	6.25	7.78e-06	3.17e-05	9|247|22|3527	PF00003;PF00027;PF00060;PF00503;PF01094;PF07562;PF07686;PF13853;PF13895
Group	GO:0060442	branching involved in prostate gland morphogenesis	3	7.33	9.17e-06	3.65e-05	5|247|6|3527	PF00046;PF00049;PF00193;PF07679;PF07714
Group	GO:0048483	autonomic nervous system development	3	6.63	9.06e-06	3.65e-05	7|247|13|3527	PF00019;PF00046;PF00320;PF00870;PF00907;PF03299;PF12444
Group	GO:0060688	regulation of morphogenesis of a branching structure	3	6.06	1.20e-05	4.69e-05	9|247|23|3527	PF00001;PF00019;PF00046;PF00110;PF00292;PF00688;PF07679;PF07714;PF12444
Group	GO:0006813	potassium ion transport	3	6.06	1.20e-05	4.69e-05	9|247|23|3527	PF00027;PF00089;PF00230;PF00520;PF01007;PF02214;PF03520;PF07885;PF13426
Group	GO:0008589	regulation of smoothened signaling pathway	3	6.24	1.22e-05	4.72e-05	8|247|18|3527	PF00046;PF01085;PF01153;PF02351;PF02460;PF07679;PF07714;PF13895
Group	GO:0045580	regulation of T cell differentiation	3	6.24	1.22e-05	4.72e-05	8|247|18|3527	PF00019;PF00041;PF00250;PF00320;PF00688;PF01085;PF01415;PF07714
Group	GO:0001837	epithelial to mesenchymal transition	3	6.24	1.22e-05	4.72e-05	8|247|18|3527	PF00010;PF00019;PF00110;PF00167;PF00530;PF00688;PF01833;PF12444
Group	GO:0010470	regulation of gastrulation	3	6.32	1.70e-05	6.42e-05	7|247|14|3527	PF00010;PF00046;PF00250;PF00386;PF01391;PF03529;PF07714
Group	GO:0003382	epithelial cell morphogenesis	3	6.32	1.70e-05	6.42e-05	7|247|14|3527	PF00019;PF00024;PF00100;PF00292;PF00320;PF00688;PF01392
Group	GO:0060079	regulation of excitatory postsynaptic membrane potential	3	6.32	1.70e-05	6.42e-05	7|247|14|3527	PF00060;PF00135;PF00497;PF01094;PF02210;PF10565;PF10613
Group	GO:0048771	tissue remodeling	3	6.32	1.70e-05	6.42e-05	7|247|14|3527	PF00001;PF00010;PF00049;PF00167;PF00688;PF01415;PF07714
Group	GO:0032649	regulation of interferon-gamma production	3	6.58	1.84e-05	6.74e-05	6|247|10|3527	PF00100;PF00250;PF00560;PF01510;PF13855;PF13927
Group	GO:0060425	lung morphogenesis	3	6.58	1.84e-05	6.74e-05	6|247|10|3527	PF00010;PF00049;PF00167;PF00320;PF07679;PF07714
Group	GO:0072102	glomerulus morphogenesis	3	6.58	1.84e-05	6.74e-05	6|247|10|3527	PF00010;PF00019;PF00688;PF07679;PF07714;PF13895
Group	GO:0001823	mesonephros development	3	6.58	1.84e-05	6.74e-05	6|247|10|3527	PF00046;PF00110;PF00167;PF00292;PF00320;PF00688
Group	GO:0060411	cardiac septum morphogenesis	3	6.58	1.84e-05	6.74e-05	6|247|10|3527	PF00010;PF00110;PF00907;PF07645;PF07679;PF07714
Group	GO:0070664	negative regulation of leukocyte proliferation	3	6.58	1.84e-05	6.74e-05	6|247|10|3527	PF00019;PF00250;PF00688;PF07686;PF13895;PF13927
Group	GO:0007565	female pregnancy	3	5.87	1.81e-05	6.74e-05	9|247|24|3527	PF00001;PF00045;PF00053;PF00055;PF00089;PF00413;PF01471;PF07686;PF13895
Group	GO:0007569	cell aging	3	6.01	1.99e-05	7.22e-05	8|247|19|3527	PF00010;PF00040;PF00059;PF00870;PF00907;PF01431;PF05649;PF07710
Group	GO:0061039	ovum-producing ovary development	3	6.01	1.99e-05	7.22e-05	8|247|19|3527	PF00019;PF00250;PF00688;PF01421;PF07679;PF07714;PF13895;PF13927
Group	GO:0038093	Fc receptor signaling pathway	3	7.29	2.35e-05	8.15e-05	4|247|4|3527	PF07679;PF07714;PF13895;PF13927
Group	GO:0038109	Kit signaling pathway	3	7.29	2.35e-05	8.15e-05	4|247|4|3527	PF07679;PF07714;PF13895;PF13927
Group	GO:0007419	ventral cord development	3	7.29	2.35e-05	8.15e-05	4|247|4|3527	PF07679;PF07686;PF07714;PF13895
Group	GO:0060462	lung lobe development	3	7.29	2.35e-05	8.15e-05	4|247|4|3527	PF00049;PF00320;PF07679;PF07714
Group	GO:0072148	epithelial cell fate commitment	3	7.29	2.35e-05	8.15e-05	4|247|4|3527	PF00320;PF07679;PF07714;PF13895
Group	GO:0043576	regulation of respiratory gaseous exchange	3	6.68	3.03e-05	1.02e-04	5|247|7|3527	PF00046;PF00060;PF00135;PF00497;PF01094
Group	GO:0031033	myosin filament organization	3	6.68	3.03e-05	1.02e-04	5|247|7|3527	PF00041;PF00063;PF01576;PF02736;PF07679
Group	GO:0051291	protein heterooligomerization	3	6.68	3.03e-05	1.02e-04	5|247|7|3527	PF00041;PF00042;PF00386;PF01391;PF07714
Group	GO:0060840	artery development	3	6.03	3.00e-05	1.02e-04	7|247|15|3527	PF00010;PF00019;PF00046;PF00167;PF00688;PF00907;PF03299
Group	GO:0048520	positive regulation of behavior	3	6.03	3.00e-05	1.02e-04	7|247|15|3527	PF00001;PF00019;PF00027;PF00048;PF00520;PF00688;PF13895
Group	GO:2000243	positive regulation of reproductive process	3	6.03	3.00e-05	1.02e-04	7|247|15|3527	PF00001;PF00019;PF00063;PF00089;PF00100;PF00688;PF12444
Group	GO:0045471	response to ethanol	3	5.80	3.11e-05	1.04e-04	8|247|20|3527	PF00001;PF00060;PF00497;PF00520;PF01094;PF02931;PF07714;PF10565
Group	GO:0071383	cellular response to steroid hormone stimulus	3	5.80	3.11e-05	1.04e-04	8|247|20|3527	PF00019;PF00046;PF00201;PF00230;PF00560;PF00688;PF05729;PF07714
Group	GO:0001570	vasculogenesis	3	5.80	3.11e-05	1.04e-04	8|247|20|3527	PF00100;PF00110;PF00907;PF00992;PF01392;PF01534;PF07645;PF07714
Group	GO:0031016	pancreas development	3	5.80	3.11e-05	1.04e-04	8|247|20|3527	PF00010;PF00041;PF00046;PF00049;PF00250;PF00292;PF01392;PF01534
Group	GO:0048640	negative regulation of developmental growth	3	6.19	3.81e-05	1.26e-04	6|247|11|3527	PF00019;PF00110;PF00167;PF00622;PF00688;PF02210
Group	GO:0033993	response to lipid	3	6.19	3.81e-05	1.26e-04	6|247|11|3527	PF00001;PF00019;PF00048;PF00061;PF00067;PF00688
Group	GO:0014013	regulation of gliogenesis	3	5.60	4.72e-05	1.55e-04	8|247|21|3527	PF00001;PF00010;PF00041;PF00046;PF07679;PF07714;PF12444;PF13895
Group	GO:0061053	somite development	3	5.60	4.72e-05	1.55e-04	8|247|21|3527	PF00010;PF00046;PF00250;PF00615;PF00870;PF00907;PF01085;PF01392
Group	GO:0051101	regulation of DNA binding	3	5.77	5.03e-05	1.63e-04	7|247|16|3527	PF00010;PF00019;PF00046;PF00320;PF00688;PF01534;PF07645
Group	GO:0018108	peptidyl-tyrosine phosphorylation	3	5.41	6.98e-05	2.23e-04	8|247|22|3527	PF00001;PF00041;PF01404;PF07645;PF07679;PF07714;PF13895;PF13927
Group	GO:0002275	myeloid cell activation involved in immune response	3	5.85	7.17e-05	2.25e-04	6|247|12|3527	PF00048;PF07679;PF07714;PF13855;PF13895;PF13927
Group	GO:0001945	lymph vessel development	3	5.85	7.17e-05	2.25e-04	6|247|12|3527	PF00250;PF00907;PF07645;PF07679;PF07714;PF13895
Group	GO:0030509	BMP signaling pathway	3	5.85	7.17e-05	2.25e-04	6|247|12|3527	PF00010;PF00019;PF00046;PF00167;PF00688;PF02736
Group	GO:0030199	collagen fibril organization	3	5.85	7.17e-05	2.25e-04	6|247|12|3527	PF00010;PF00530;PF01391;PF01410;PF01421;PF01562
Group	GO:0060070	canonical Wnt receptor signaling pathway	3	5.85	7.17e-05	2.25e-04	6|247|12|3527	PF00049;PF00057;PF00110;PF00167;PF00320;PF02736
Group	GO:0048644	muscle organ morphogenesis	3	6.16	7.61e-05	2.34e-04	5|247|8|3527	PF00110;PF00907;PF00992;PF07679;PF07714
Group	GO:0032890	regulation of organic acid transport	3	6.16	7.61e-05	2.34e-04	5|247|8|3527	PF00040;PF00059;PF01094;PF07714;PF10613
Group	GO:0072132	mesenchyme morphogenesis	3	6.16	7.61e-05	2.34e-04	5|247|8|3527	PF00010;PF00019;PF00167;PF00688;PF12444
Group	GO:0048066	developmental pigmentation	3	5.53	8.04e-05	2.44e-04	7|247|17|3527	PF00010;PF00071;PF00292;PF07714;PF12444;PF13895;PF13927
Group	GO:0031670	cellular response to nutrient	3	5.53	8.04e-05	2.44e-04	7|247|17|3527	PF00110;PF00230;PF00292;PF01392;PF01534;PF07714;PF12444
Group	GO:0050920	regulation of chemotaxis	3	5.53	8.04e-05	2.44e-04	7|247|17|3527	PF00001;PF00019;PF00048;PF00110;PF00688;PF01833;PF02210
Group	GO:0030183	B cell differentiation	3	5.53	8.04e-05	2.44e-04	7|247|17|3527	PF00337;PF00870;PF07679;PF07714;PF13855;PF13895;PF13927
Group	GO:0055088	lipid homeostasis	3	5.24	1.01e-04	3.01e-04	8|247|23|3527	PF00001;PF00010;PF00057;PF00067;PF00151;PF01347;PF01442;PF02460
Group	GO:0060363	cranial suture morphogenesis	3	6.40	1.11e-04	3.24e-04	4|247|5|3527	PF00019;PF00688;PF07679;PF07714
Group	GO:0022617	extracellular matrix disassembly	3	6.40	1.11e-04	3.24e-04	4|247|5|3527	PF00045;PF00089;PF00413;PF01471
Group	GO:0038162	erythropoietin-mediated signaling pathway	3	6.40	1.11e-04	3.24e-04	4|247|5|3527	PF07679;PF07714;PF13895;PF13927
Group	GO:0090136	epithelial cell-cell adhesion	3	6.40	1.11e-04	3.24e-04	4|247|5|3527	PF07679;PF07714;PF13895;PF13927
Group	GO:0032368	regulation of lipid transport	3	5.54	1.25e-04	3.54e-04	6|247|13|3527	PF00040;PF00059;PF00386;PF01391;PF02460;PF07714
Group	GO:0003073	regulation of systemic arterial blood pressure	3	5.54	1.25e-04	3.54e-04	6|247|13|3527	PF00001;PF00041;PF00067;PF00079;PF00089;PF00992
Group	GO:0051100	negative regulation of binding	3	5.54	1.25e-04	3.54e-04	6|247|13|3527	PF00001;PF00010;PF00046;PF00386;PF01391;PF01534
Group	GO:0090130	tissue migration	3	5.54	1.25e-04	3.54e-04	6|247|13|3527	PF00001;PF00167;PF07679;PF07714;PF13895;PF13927
Group	GO:0009187	cyclic nucleotide metabolic process	3	5.54	1.25e-04	3.54e-04	6|247|13|3527	PF00001;PF00211;PF00230;PF01094;PF06327;PF07714
Group	GO:0048709	oligodendrocyte differentiation	3	5.54	1.25e-04	3.54e-04	6|247|13|3527	PF00010;PF00046;PF00292;PF07679;PF12444;PF13895
Group	GO:0003231	cardiac ventricle development	3	5.31	1.24e-04	3.54e-04	7|247|18|3527	PF00110;PF00250;PF00320;PF00992;PF01392;PF07679;PF07714
Group	GO:0045807	positive regulation of endocytosis	3	5.31	1.24e-04	3.54e-04	7|247|18|3527	PF00031;PF00048;PF00059;PF01391;PF02210;PF07686;PF13895
Group	GO:0050773	regulation of dendrite development	3	5.31	1.24e-04	3.54e-04	7|247|18|3527	PF00060;PF00135;PF00497;PF01094;PF02931;PF02932;PF10409
Group	GO:0001894	tissue homeostasis	3	5.07	1.42e-04	3.99e-04	8|247|24|3527	PF00001;PF00046;PF00059;PF01391;PF01415;PF07686;PF12444;PF13895
Group	GO:0043506	regulation of JUN kinase activity	3	5.71	1.62e-04	4.35e-04	5|247|9|3527	PF00049;PF00110;PF00615;PF01392;PF01534
Group	GO:0043277	apoptotic cell clearance	3	5.71	1.62e-04	4.35e-04	5|247|9|3527	PF00053;PF00057;PF07645;PF07714;PF13927
Group	GO:0038084	vascular endothelial growth factor signaling pathway	3	5.71	1.62e-04	4.35e-04	5|247|9|3527	PF00431;PF07679;PF07686;PF07714;PF13895
Group	GO:0070252	actin-mediated cell contraction	3	5.71	1.62e-04	4.35e-04	5|247|9|3527	PF00024;PF00041;PF00100;PF00992;PF07679
Group	GO:0030540	female genitalia development	3	5.71	1.62e-04	4.35e-04	5|247|9|3527	PF00041;PF00046;PF00870;PF07714;PF13895
Group	GO:0060428	lung epithelium development	3	5.71	1.62e-04	4.35e-04	5|247|9|3527	PF00049;PF00110;PF07679;PF07714;PF13895
Group	GO:0043542	endothelial cell migration	3	5.71	1.62e-04	4.35e-04	5|247|9|3527	PF00063;PF00530;PF00930;PF01576;PF02736
Group	GO:0032677	regulation of interleukin-8 production	3	5.71	1.62e-04	4.35e-04	5|247|9|3527	PF00001;PF00386;PF00560;PF01391;PF13855
Group	GO:0003197	endocardial cushion development	3	5.71	1.62e-04	4.35e-04	5|247|9|3527	PF00010;PF00167;PF00320;PF07645;PF12444
Group	GO:0035176	social behavior	3	5.71	1.62e-04	4.35e-04	5|247|9|3527	PF00060;PF00135;PF00497;PF00907;PF01094
Group	GO:0021532	neural tube patterning	3	5.71	1.62e-04	4.35e-04	5|247|9|3527	PF00010;PF00046;PF00110;PF00167;PF00292
Group	GO:2000278	regulation of DNA biosynthetic process	3	5.71	1.62e-04	4.35e-04	5|247|9|3527	PF00010;PF00386;PF01391;PF07679;PF07714
Group	GO:0007157	heterophilic cell-cell adhesion	3	5.71	1.62e-04	4.35e-04	5|247|9|3527	PF00059;PF07679;PF07686;PF13855;PF13895
Group	GO:0009746	response to hexose stimulus	3	5.11	1.84e-04	4.88e-04	7|247|19|3527	PF00046;PF00067;PF00230;PF00386;PF00503;PF01391;PF13895
Group	GO:0009593	detection of chemical stimulus	3	5.11	1.84e-04	4.88e-04	7|247|19|3527	PF00003;PF00060;PF00503;PF07562;PF13516;PF13853;PF13855
Group	GO:0042476	odontogenesis	3	5.11	1.84e-04	4.88e-04	7|247|19|3527	PF00019;PF00688;PF00870;PF00907;PF01391;PF07679;PF07714
Group	GO:0001649	osteoblast differentiation	3	5.11	1.84e-04	4.88e-04	7|247|19|3527	PF00019;PF00048;PF00110;PF00688;PF01392;PF01534;PF12444
Group	GO:0031345	negative regulation of cell projection organization	3	5.11	1.84e-04	4.88e-04	7|247|19|3527	PF00041;PF00110;PF00167;PF01404;PF01979;PF02210;PF13855
Group	GO:0051048	negative regulation of secretion	3	4.91	1.96e-04	5.15e-04	8|247|25|3527	PF00001;PF00019;PF00061;PF00250;PF00622;PF00688;PF01833;PF13895
Group	GO:0051897	positive regulation of protein kinase B signaling cascade	3	5.27	2.07e-04	5.39e-04	6|247|14|3527	PF00019;PF00049;PF00061;PF00100;PF00320;PF00688
Group	GO:0002695	negative regulation of leukocyte activation	3	5.27	2.07e-04	5.39e-04	6|247|14|3527	PF00019;PF00250;PF00688;PF01510;PF13895;PF13927
Group	GO:0030595	leukocyte chemotaxis	3	4.92	2.67e-04	6.82e-04	7|247|20|3527	PF00001;PF00019;PF00041;PF00048;PF00063;PF00688;PF07686
Group	GO:0070983	dendrite guidance	3	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00041;PF00046;PF07679
Group	GO:0007561	imaginal disc eversion	3	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00045;PF00413;PF01471
Group	GO:0048755	branching morphogenesis of a nerve	3	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF01404;PF07679;PF07714
Group	GO:0035172	hemocyte proliferation	3	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF07679;PF07686;PF07714
Group	GO:0060037	pharyngeal system development	3	5.73	3.15e-04	7.45e-04	4|247|6|3527	PF00046;PF00167;PF00320;PF00907
Group	GO:0034381	plasma lipoprotein particle clearance	3	5.73	3.15e-04	7.45e-04	4|247|6|3527	PF00057;PF00386;PF01391;PF07645
Group	GO:0072077	renal vesicle morphogenesis	3	5.73	3.15e-04	7.45e-04	4|247|6|3527	PF00019;PF00046;PF00292;PF00688
Group	GO:0045576	mast cell activation	3	5.73	3.15e-04	7.45e-04	4|247|6|3527	PF07679;PF07714;PF13895;PF13927
Group	GO:0032732	positive regulation of interleukin-1 production	3	5.73	3.15e-04	7.45e-04	4|247|6|3527	PF00048;PF02758;PF05729;PF13516
Group	GO:0010002	cardioblast differentiation	3	5.73	3.15e-04	7.45e-04	4|247|6|3527	PF01431;PF05649;PF07679;PF13895
Group	GO:0030219	megakaryocyte differentiation	3	5.73	3.15e-04	7.45e-04	4|247|6|3527	PF07679;PF07714;PF13895;PF13927
Group	GO:0007200	phospholipase C-activating G-protein coupled receptor signaling pathway	3	5.33	3.05e-04	7.45e-04	5|247|10|3527	PF00001;PF00003;PF00503;PF01094;PF07562
Group	GO:0002444	myeloid leukocyte mediated immunity	3	5.33	3.05e-04	7.45e-04	5|247|10|3527	PF00048;PF07679;PF07714;PF13895;PF13927
Group	GO:0035249	synaptic transmission, glutamatergic	3	5.33	3.05e-04	7.45e-04	5|247|10|3527	PF00060;PF00497;PF00520;PF01094;PF10613
Group	GO:0035010	encapsulation of foreign target	3	5.33	3.05e-04	7.45e-04	5|247|10|3527	PF00041;PF00071;PF01404;PF07714;PF10409
Group	GO:0045778	positive regulation of ossification	3	5.33	3.05e-04	7.45e-04	5|247|10|3527	PF00019;PF00110;PF00688;PF03299;PF07645
Group	GO:0090109	regulation of cell-substrate junction assembly	3	5.33	3.05e-04	7.45e-04	5|247|10|3527	PF00041;PF00061;PF01404;PF07714;PF10409
Group	GO:0007622	rhythmic behavior	3	5.33	3.05e-04	7.45e-04	5|247|10|3527	PF00001;PF00010;PF00027;PF00061;PF00520
Group	GO:0042036	negative regulation of cytokine biosynthetic process	3	5.33	3.05e-04	7.45e-04	5|247|10|3527	PF00001;PF00019;PF00250;PF00688;PF13895
Group	GO:0003179	heart valve morphogenesis	3	5.33	3.05e-04	7.45e-04	5|247|10|3527	PF00010;PF00320;PF00907;PF07645;PF12444
Group	GO:0032651	regulation of interleukin-1 beta production	3	5.33	3.05e-04	7.45e-04	5|247|10|3527	PF00001;PF00048;PF02758;PF05729;PF13516
Group	GO:0051784	negative regulation of nuclear division	3	5.33	3.05e-04	7.45e-04	5|247|10|3527	PF00019;PF00688;PF07679;PF07714;PF13895
Group	GO:0021545	cranial nerve development	3	5.02	3.24e-04	7.45e-04	6|247|15|3527	PF00041;PF00046;PF00907;PF01404;PF03299;PF07714
Group	GO:0003156	regulation of organ formation	3	5.02	3.24e-04	7.45e-04	6|247|15|3527	PF00010;PF00019;PF00046;PF00110;PF00167;PF00688
Group	GO:0061035	regulation of cartilage development	3	5.02	3.24e-04	7.45e-04	6|247|15|3527	PF00010;PF00019;PF00530;PF00688;PF07645;PF12444
Group	GO:0030901	midbrain development	3	5.02	3.24e-04	7.45e-04	6|247|15|3527	PF00046;PF00110;PF00250;PF03529;PF07679;PF07714
Group	GO:0006954	inflammatory response	3	4.62	3.56e-04	7.80e-04	8|247|27|3527	PF00001;PF00031;PF00048;PF00089;PF00193;PF01023;PF07714;PF13895
Group	GO:0071482	cellular response to light stimulus	3	4.74	3.77e-04	8.15e-04	7|247|21|3527	PF00010;PF00230;PF00870;PF01431;PF05649;PF07710;PF13426
Group	GO:0001764	neuron migration	3	4.74	3.77e-04	8.15e-04	7|247|21|3527	PF00002;PF00046;PF00292;PF00918;PF01275;PF02736;PF12003
Group	GO:0050731	positive regulation of peptidyl-tyrosine phosphorylation	3	4.74	3.77e-04	8.15e-04	7|247|21|3527	PF00010;PF00041;PF02210;PF07714;PF11527;PF13895;PF13927
Group	GO:0042552	myelination	3	4.49	4.69e-04	1.01e-03	8|247|28|3527	PF00010;PF00041;PF01421;PF01562;PF07679;PF07714;PF08516;PF13895
Group	GO:0021510	spinal cord development	3	4.79	4.89e-04	1.03e-03	6|247|16|3527	PF00046;PF00110;PF00292;PF00520;PF01534;PF07645
Group	GO:0031341	regulation of cell killing	3	4.79	4.89e-04	1.03e-03	6|247|16|3527	PF00041;PF00059;PF00129;PF07686;PF13895;PF13927
Group	GO:0006937	regulation of muscle contraction	3	4.79	4.89e-04	1.03e-03	6|247|16|3527	PF00001;PF00068;PF00992;PF02931;PF02932;PF07686
Group	GO:2000377	regulation of reactive oxygen species metabolic process	3	4.79	4.89e-04	1.03e-03	6|247|16|3527	PF00001;PF00560;PF03299;PF07714;PF13516;PF13855
Group	GO:0006509	membrane protein ectodomain proteolysis	3	4.79	4.89e-04	1.03e-03	6|247|16|3527	PF00063;PF01421;PF01562;PF01576;PF02736;PF08516
Group	GO:0045598	regulation of fat cell differentiation	3	4.79	4.89e-04	1.03e-03	6|247|16|3527	PF00019;PF00110;PF00320;PF00386;PF00688;PF01391
Group	GO:0007492	endoderm development	3	4.79	4.89e-04	1.03e-03	6|247|16|3527	PF00019;PF00046;PF00147;PF00167;PF00320;PF00688
Group	GO:0048168	regulation of neuronal synaptic plasticity	3	4.79	4.89e-04	1.03e-03	6|247|16|3527	PF00003;PF00060;PF00071;PF01094;PF07562;PF10613
Group	GO:0048645	organ formation	3	5.00	5.27e-04	1.09e-03	5|247|11|3527	PF00041;PF00292;PF00870;PF07679;PF07714
Group	GO:0035264	multicellular organism growth	3	5.00	5.27e-04	1.09e-03	5|247|11|3527	PF00028;PF00049;PF00870;PF07679;PF07714
Group	GO:0006582	melanin metabolic process	3	5.00	5.27e-04	1.09e-03	5|247|11|3527	PF00041;PF00071;PF01404;PF07714;PF10409
Group	GO:0035020	regulation of Rac protein signal transduction	3	5.00	5.27e-04	1.09e-03	5|247|11|3527	PF00041;PF00071;PF01404;PF07679;PF07714
Group	GO:0048730	epidermis morphogenesis	3	5.00	5.27e-04	1.09e-03	5|247|11|3527	PF00019;PF00688;PF00870;PF07679;PF07714
Group	GO:0045055	regulated secretory pathway	3	5.00	5.27e-04	1.09e-03	5|247|11|3527	PF00048;PF07679;PF07714;PF13895;PF13927
Group	GO:0017156	calcium ion-dependent exocytosis	3	5.00	5.27e-04	1.09e-03	5|247|11|3527	PF00027;PF00089;PF00520;PF02931;PF02932
Group	GO:0007416	synapse assembly	3	4.57	5.20e-04	1.09e-03	7|247|22|3527	PF00028;PF00063;PF00135;PF00520;PF01275;PF02210;PF08266
Group	GO:0021548	pons development	3	5.20	6.94e-04	1.38e-03	4|247|7|3527	PF00060;PF00497;PF00520;PF01094
Group	GO:0048538	thymus development	3	5.20	6.94e-04	1.38e-03	4|247|7|3527	PF00046;PF00167;PF00250;PF00907
Group	GO:0030803	negative regulation of cyclic nucleotide biosynthetic process	3	5.20	6.94e-04	1.38e-03	4|247|7|3527	PF00001;PF00003;PF01094;PF07562
Group	GO:0060525	prostate glandular acinus development	3	5.20	6.94e-04	1.38e-03	4|247|7|3527	PF00049;PF00870;PF07679;PF07714
Group	GO:0035304	regulation of protein dephosphorylation	3	5.20	6.94e-04	1.38e-03	4|247|7|3527	PF00019;PF00560;PF00688;PF13855
Group	GO:0035215	genital disc development	3	5.20	6.94e-04	1.38e-03	4|247|7|3527	PF00046;PF07679;PF07686;PF07714
Group	GO:0031638	zymogen activation	3	5.20	6.94e-04	1.38e-03	4|247|7|3527	PF00045;PF00089;PF00413;PF01471
Group	GO:0035112	genitalia morphogenesis	3	5.20	6.94e-04	1.38e-03	4|247|7|3527	PF00870;PF07679;PF07686;PF07714
Group	GO:0021578	hindbrain maturation	3	5.20	6.94e-04	1.38e-03	4|247|7|3527	PF00060;PF00497;PF00520;PF01094
Group	GO:0071599	otic vesicle development	3	5.20	6.94e-04	1.38e-03	4|247|7|3527	PF00167;PF07679;PF07714;PF12444
Group	GO:0034109	homotypic cell-cell adhesion	3	5.20	6.94e-04	1.38e-03	4|247|7|3527	PF00041;PF07679;PF07714;PF13895
Group	GO:0007585	respiratory gaseous exchange	3	5.20	6.94e-04	1.38e-03	4|247|7|3527	PF00060;PF00071;PF00497;PF01094
Group	GO:0030815	negative regulation of cAMP metabolic process	3	5.20	6.94e-04	1.38e-03	4|247|7|3527	PF00001;PF00003;PF01094;PF07562
Group	GO:1900372	negative regulation of purine nucleotide biosynthetic process	3	5.20	6.94e-04	1.38e-03	4|247|7|3527	PF00001;PF00003;PF01094;PF07562
Group	GO:0032642	regulation of chemokine production	3	5.20	6.94e-04	1.38e-03	4|247|7|3527	PF00061;PF00386;PF01391;PF13855
Group	GO:0016525	negative regulation of angiogenesis	3	4.42	7.03e-04	1.39e-03	7|247|23|3527	PF00002;PF00041;PF00048;PF00079;PF00090;PF02793;PF07645
Group	GO:0007173	epidermal growth factor receptor signaling pathway	3	4.42	7.03e-04	1.39e-03	7|247|23|3527	PF00019;PF00211;PF00688;PF06327;PF07645;PF07714;PF12444
Group	GO:0014066	regulation of phosphatidylinositol 3-kinase cascade	3	4.58	7.12e-04	1.40e-03	6|247|17|3527	PF00001;PF00051;PF07679;PF07714;PF12444;PF13895
Group	GO:0021549	cerebellum development	3	4.58	7.12e-04	1.40e-03	6|247|17|3527	PF00046;PF00063;PF00110;PF00246;PF00520;PF01534
Group	GO:2000696	regulation of epithelial cell differentiation involved in kidney development	3	4.71	8.52e-04	1.65e-03	5|247|12|3527	PF00046;PF00292;PF00320;PF00386;PF01391
Group	GO:0043627	response to estrogen stimulus	3	4.71	8.52e-04	1.65e-03	5|247|12|3527	PF00045;PF00320;PF00413;PF01471;PF05729
Group	GO:0008286	insulin receptor signaling pathway	3	4.71	8.52e-04	1.65e-03	5|247|12|3527	PF00049;PF00061;PF00250;PF00613;PF10409
Group	GO:0071230	cellular response to amino acid stimulus	3	4.71	8.52e-04	1.65e-03	5|247|12|3527	PF00060;PF00497;PF01094;PF01391;PF01410
Group	GO:0007298	border follicle cell migration	3	4.71	8.52e-04	1.65e-03	5|247|12|3527	PF00071;PF01562;PF07679;PF07686;PF07714
Group	GO:0046887	positive regulation of hormone secretion	3	4.71	8.52e-04	1.65e-03	5|247|12|3527	PF00001;PF00019;PF00046;PF00123;PF00688
Group	GO:0050796	regulation of insulin secretion	3	4.27	9.34e-04	1.80e-03	7|247|24|3527	PF00019;PF00027;PF00061;PF00520;PF00688;PF02214;PF03299
Group	GO:0002699	positive regulation of immune effector process	3	4.27	9.34e-04	1.80e-03	7|247|24|3527	PF00059;PF00100;PF00129;PF00250;PF07686;PF07714;PF13895
Group	GO:0007088	regulation of mitosis	3	4.27	9.34e-04	1.80e-03	7|247|24|3527	PF00019;PF00167;PF00688;PF07679;PF07686;PF07714;PF13895
Group	GO:0006029	proteoglycan metabolic process	3	4.39	1.01e-03	1.92e-03	6|247|18|3527	PF00049;PF00685;PF02210;PF03567;PF12529;PF13855
Group	GO:0007435	salivary gland morphogenesis	3	4.39	1.01e-03	1.92e-03	6|247|18|3527	PF00167;PF01391;PF07679;PF07686;PF07714;PF10409
Group	GO:0072215	regulation of metanephros development	3	4.39	1.01e-03	1.92e-03	6|247|18|3527	PF00019;PF00292;PF00386;PF00688;PF01391;PF07714
Group	GO:2001108	positive regulation of Rho guanyl-nucleotide exchange factor activity	3	5.33	1.29e-03	2.30e-03	3|247|4|3527	PF00041;PF01404;PF07714
Group	GO:0007214	gamma-aminobutyric acid signaling pathway	3	5.33	1.29e-03	2.30e-03	3|247|4|3527	PF00520;PF02931;PF02932
Group	GO:0051231	spindle elongation	3	5.33	1.29e-03	2.30e-03	3|247|4|3527	PF07679;PF07686;PF07714
Group	GO:0045610	regulation of hemocyte differentiation	3	5.33	1.29e-03	2.30e-03	3|247|4|3527	PF07679;PF07686;PF07714
Group	GO:0032291	axon ensheathment in central nervous system	3	5.33	1.29e-03	2.30e-03	3|247|4|3527	PF00010;PF07679;PF13895
Group	GO:0060484	lung-associated mesenchyme development	3	5.33	1.29e-03	2.30e-03	3|247|4|3527	PF07679;PF07714;PF13895
Group	GO:0051932	synaptic transmission, GABAergic	3	5.33	1.29e-03	2.30e-03	3|247|4|3527	PF00520;PF02931;PF02932
Group	GO:0030216	keratinocyte differentiation	3	4.77	1.31e-03	2.30e-03	4|247|8|3527	PF00038;PF00292;PF00870;PF03299
Group	GO:0072178	nephric duct morphogenesis	3	4.77	1.31e-03	2.30e-03	4|247|8|3527	PF00019;PF00046;PF00320;PF00688
Group	GO:0010717	regulation of epithelial to mesenchymal transition	3	4.77	1.31e-03	2.30e-03	4|247|8|3527	PF00019;PF00089;PF00688;PF01404
Group	GO:0000186	activation of MAPKK activity	3	4.77	1.31e-03	2.30e-03	4|247|8|3527	PF00001;PF00019;PF00167;PF00688
Group	GO:0010453	regulation of cell fate commitment	3	4.77	1.31e-03	2.30e-03	4|247|8|3527	PF00046;PF00292;PF07679;PF07714
Group	GO:0051492	regulation of stress fiber assembly	3	4.77	1.31e-03	2.30e-03	4|247|8|3527	PF00001;PF00041;PF00110;PF01404
Group	GO:0030539	male genitalia development	3	4.77	1.31e-03	2.30e-03	4|247|8|3527	PF00167;PF07679;PF07686;PF07714
Group	GO:0050918	positive chemotaxis	3	4.77	1.31e-03	2.30e-03	4|247|8|3527	PF00019;PF00048;PF00167;PF00688
Group	GO:0003338	metanephros morphogenesis	3	4.77	1.31e-03	2.30e-03	4|247|8|3527	PF00019;PF00292;PF00688;PF12444
Group	GO:0022408	negative regulation of cell-cell adhesion	3	4.77	1.31e-03	2.30e-03	4|247|8|3527	PF00019;PF00386;PF00688;PF01391
Group	GO:0060761	negative regulation of response to cytokine stimulus	3	4.77	1.31e-03	2.30e-03	4|247|8|3527	PF00041;PF00386;PF01391;PF02210
Group	GO:0048443	stamen development	3	4.77	1.31e-03	2.30e-03	4|247|8|3527	PF00560;PF07714;PF13516;PF13855
Group	GO:0006775	fat-soluble vitamin metabolic process	3	4.45	1.31e-03	2.30e-03	5|247|13|3527	PF00061;PF00067;PF00201;PF01273;PF03765
Group	GO:0033057	multicellular organismal reproductive behavior	3	4.45	1.31e-03	2.30e-03	5|247|13|3527	PF00060;PF00497;PF00520;PF00858;PF01094
Group	GO:0032350	regulation of hormone metabolic process	3	4.45	1.31e-03	2.30e-03	5|247|13|3527	PF00079;PF00089;PF00292;PF00320;PF00520
Group	GO:0030177	positive regulation of Wnt receptor signaling pathway	3	4.45	1.31e-03	2.30e-03	5|247|13|3527	PF01153;PF01391;PF07679;PF07714;PF13895
Group	GO:0007520	myoblast fusion	3	4.45	1.31e-03	2.30e-03	5|247|13|3527	PF00041;PF00520;PF07679;PF07686;PF13895
Group	GO:2000177	regulation of neural precursor cell proliferation	3	4.45	1.31e-03	2.30e-03	5|247|13|3527	PF00010;PF00046;PF00049;PF00292;PF00870
Group	GO:0035265	organ growth	3	4.45	1.31e-03	2.30e-03	5|247|13|3527	PF00019;PF00167;PF00688;PF07679;PF07714
Group	GO:0008063	Toll signaling pathway	3	4.45	1.31e-03	2.30e-03	5|247|13|3527	PF00079;PF00089;PF00560;PF13306;PF13855
Group	GO:0072002	Malpighian tubule development	3	4.45	1.31e-03	2.30e-03	5|247|13|3527	PF00010;PF00907;PF07679;PF07686;PF07714
Group	GO:0043687	post-translational protein modification	3	4.21	1.39e-03	2.41e-03	6|247|19|3527	PF00089;PF00094;PF00246;PF00777;PF01390;PF01762
Group	GO:0007338	single fertilization	3	4.21	1.39e-03	2.41e-03	6|247|19|3527	PF00084;PF00089;PF00100;PF01562;PF02931;PF02932
Group	GO:0007050	cell cycle arrest	3	4.21	1.39e-03	2.41e-03	6|247|19|3527	PF00019;PF00048;PF00688;PF00870;PF07645;PF07710
Group	GO:0006109	regulation of carbohydrate metabolic process	3	3.99	1.57e-03	2.73e-03	7|247|26|3527	PF00001;PF00010;PF00049;PF00061;PF00386;PF01391;PF03370
Group	GO:0007617	mating behavior	3	4.04	1.86e-03	3.22e-03	6|247|20|3527	PF00060;PF00351;PF00497;PF00520;PF00858;PF01094
Group	GO:0042108	positive regulation of cytokine biosynthetic process	3	4.22	1.92e-03	3.27e-03	5|247|14|3527	PF00560;PF07686;PF13516;PF13855;PF13895
Group	GO:0002118	aggressive behavior	3	4.22	1.92e-03	3.27e-03	5|247|14|3527	PF00560;PF13306;PF13855;PF13895;PF13927
Group	GO:0030516	regulation of axon extension	3	4.22	1.92e-03	3.27e-03	5|247|14|3527	PF00110;PF00435;PF01562;PF13895;PF13927
Group	GO:0001889	liver development	3	4.22	1.92e-03	3.27e-03	5|247|14|3527	PF00046;PF00094;PF00201;PF01826;PF08742
Group	GO:0033555	multicellular organismal response to stress	3	4.22	1.92e-03	3.27e-03	5|247|14|3527	PF00001;PF00060;PF00520;PF01094;PF10613
Group	GO:0034332	adherens junction organization	3	4.22	1.92e-03	3.27e-03	5|247|14|3527	PF00028;PF01049;PF07679;PF07714;PF13895
Group	GO:0001906	cell killing	3	4.41	2.23e-03	3.76e-03	4|247|9|3527	PF00059;PF00089;PF00273;PF13895
Group	GO:0010463	mesenchymal cell proliferation	3	4.41	2.23e-03	3.76e-03	4|247|9|3527	PF00019;PF00688;PF07679;PF07714
Group	GO:0050819	negative regulation of coagulation	3	4.41	2.23e-03	3.76e-03	4|247|9|3527	PF00051;PF00079;PF00089;PF07645
Group	GO:0007588	excretion	3	4.41	2.23e-03	3.76e-03	4|247|9|3527	PF00230;PF00520;PF02931;PF02932
Group	GO:0043278	response to morphine	3	4.41	2.23e-03	3.76e-03	4|247|9|3527	PF00001;PF00060;PF00497;PF01094
Group	GO:0016339	calcium-dependent cell-cell adhesion	3	4.41	2.23e-03	3.76e-03	4|247|9|3527	PF00028;PF01049;PF02210;PF08266
Group	GO:0007616	long-term memory	3	4.41	2.23e-03	3.76e-03	4|247|9|3527	PF00060;PF00497;PF00530;PF01094
Group	GO:0007530	sex determination	3	3.88	2.46e-03	4.11e-03	6|247|21|3527	PF00010;PF00041;PF00250;PF00751;PF07714;PF12444
Group	GO:0018958	phenol-containing compound metabolic process	3	3.88	2.46e-03	4.11e-03	6|247|21|3527	PF00001;PF00019;PF00320;PF00351;PF00688;PF03098
Group	GO:0050768	negative regulation of neurogenesis	3	3.88	2.46e-03	4.11e-03	6|247|21|3527	PF00010;PF00110;PF00167;PF00870;PF01404;PF07679
Group	GO:0046777	protein autophosphorylation	3	3.75	2.51e-03	4.19e-03	7|247|28|3527	PF00041;PF00063;PF01404;PF07714;PF13426;PF13895;PF13927
Group	GO:0002440	production of molecular mediator of immune response	3	4.00	2.71e-03	4.48e-03	5|247|15|3527	PF00010;PF07679;PF07714;PF13895;PF13927
Group	GO:0045621	positive regulation of lymphocyte differentiation	3	4.00	2.71e-03	4.48e-03	5|247|15|3527	PF00041;PF00320;PF01085;PF01415;PF07714
Group	GO:0061318	renal filtration cell differentiation	3	4.00	2.71e-03	4.48e-03	5|247|15|3527	PF00041;PF01562;PF07679;PF07686;PF13895
Group	GO:0051965	positive regulation of synapse assembly	3	4.00	2.71e-03	4.48e-03	5|247|15|3527	PF00041;PF00135;PF01404;PF04505;PF07714
Group	GO:0072659	protein localization to plasma membrane	3	4.00	2.71e-03	4.48e-03	5|247|15|3527	PF00071;PF00167;PF00386;PF01391;PF02210
Group	GO:0007216	G-protein coupled glutamate receptor signaling pathway	3	4.65	3.05e-03	4.90e-03	3|247|5|3527	PF00003;PF01094;PF07562
Group	GO:0070206	protein trimerization	3	4.65	3.05e-03	4.90e-03	3|247|5|3527	PF00386;PF00622;PF01391
Group	GO:0018149	peptide cross-linking	3	4.65	3.05e-03	4.90e-03	3|247|5|3527	PF00868;PF00927;PF01841
Group	GO:0001661	conditioned taste aversion	3	4.65	3.05e-03	4.90e-03	3|247|5|3527	PF00060;PF00497;PF01094
Group	GO:0002067	glandular epithelial cell differentiation	3	4.65	3.05e-03	4.90e-03	3|247|5|3527	PF00870;PF07679;PF07714
Group	GO:0060384	innervation	3	4.65	3.05e-03	4.90e-03	3|247|5|3527	PF07679;PF07714;PF13895
Group	GO:0048036	central complex development	3	4.65	3.05e-03	4.90e-03	3|247|5|3527	PF00041;PF07679;PF13895
Group	GO:0060491	regulation of cell projection assembly	3	3.74	3.19e-03	5.09e-03	6|247|22|3527	PF00001;PF00063;PF00071;PF01275;PF01979;PF07714
Group	GO:0060021	palate development	3	3.74	3.19e-03	5.09e-03	6|247|22|3527	PF00010;PF00019;PF00110;PF00688;PF00907;PF03299
Group	GO:0055012	ventricular cardiac muscle cell differentiation	3	4.09	3.52e-03	5.54e-03	4|247|10|3527	PF00038;PF00046;PF00063;PF02736
Group	GO:0045682	regulation of epidermis development	3	4.09	3.52e-03	5.54e-03	4|247|10|3527	PF00019;PF00046;PF00688;PF00870
Group	GO:0008045	motor axon guidance	3	4.09	3.52e-03	5.54e-03	4|247|10|3527	PF00046;PF00431;PF01400;PF07645
Group	GO:0009595	detection of biotic stimulus	3	4.09	3.52e-03	5.54e-03	4|247|10|3527	PF01510;PF05729;PF13516;PF13855
Group	GO:0035567	non-canonical Wnt receptor signaling pathway	3	4.09	3.52e-03	5.54e-03	4|247|10|3527	PF00110;PF01392;PF01534;PF07714
Group	GO:0030101	natural killer cell activation	3	4.09	3.52e-03	5.54e-03	4|247|10|3527	PF00010;PF00041;PF00059;PF13927
Group	GO:0051057	positive regulation of small GTPase mediated signal transduction	3	4.09	3.52e-03	5.54e-03	4|247|10|3527	PF00001;PF00071;PF00560;PF13855
Group	GO:0060736	prostate gland growth	3	4.09	3.52e-03	5.54e-03	4|247|10|3527	PF00049;PF07679;PF07714;PF12444
Group	GO:0043271	negative regulation of ion transport	3	3.81	3.72e-03	5.78e-03	5|247|16|3527	PF00001;PF00503;PF02898;PF13895;PF13927
Group	GO:0000187	activation of MAPK activity	3	3.81	3.72e-03	5.78e-03	5|247|16|3527	PF00001;PF00049;PF00167;PF13516;PF13927
Group	GO:0045444	fat cell differentiation	3	3.81	3.72e-03	5.78e-03	5|247|16|3527	PF00019;PF00386;PF00688;PF01391;PF12444
Group	GO:0042752	regulation of circadian rhythm	3	3.81	3.72e-03	5.78e-03	5|247|16|3527	PF00001;PF00010;PF00027;PF00061;PF00520
Group	GO:0006821	chloride transport	3	3.81	3.72e-03	5.78e-03	5|247|16|3527	PF01062;PF02931;PF02932;PF08434;PF09315
Group	GO:0022602	ovulation cycle process	3	3.81	3.72e-03	5.78e-03	5|247|16|3527	PF00019;PF00250;PF00688;PF01392;PF01421
Group	GO:0034311	diol metabolic process	3	3.81	3.72e-03	5.78e-03	5|247|16|3527	PF00001;PF00019;PF00320;PF00351;PF00688
Group	GO:0042462	eye photoreceptor cell development	3	3.81	3.72e-03	5.78e-03	5|247|16|3527	PF00063;PF00292;PF00503;PF02210;PF10409
Group	GO:0030326	embryonic limb morphogenesis	3	3.63	4.98e-03	7.69e-03	5|247|17|3527	PF00057;PF00110;PF00503;PF00870;PF00907
Group	GO:0001959	regulation of cytokine-mediated signaling pathway	3	3.82	5.23e-03	7.84e-03	4|247|11|3527	PF00041;PF00386;PF01391;PF02210
Group	GO:0009950	dorsal/ventral axis specification	3	3.82	5.23e-03	7.84e-03	4|247|11|3527	PF00057;PF00110;PF00292;PF00615
Group	GO:0031960	response to corticosteroid stimulus	3	3.82	5.23e-03	7.84e-03	4|247|11|3527	PF00019;PF00201;PF00230;PF01391
Group	GO:0002026	regulation of the force of heart contraction	3	3.82	5.23e-03	7.84e-03	4|247|11|3527	PF00001;PF00615;PF01699;PF02736
Group	GO:0033238	regulation of cellular amine metabolic process	3	3.82	5.23e-03	7.84e-03	4|247|11|3527	PF00001;PF00089;PF00292;PF00320
Group	GO:0002685	regulation of leukocyte migration	3	3.82	5.23e-03	7.84e-03	4|247|11|3527	PF00001;PF00048;PF00061;PF00100
Group	GO:0032321	positive regulation of Rho GTPase activity	3	3.82	5.23e-03	7.84e-03	4|247|11|3527	PF00041;PF00063;PF01404;PF07714
Group	GO:0001778	plasma membrane repair	3	3.82	5.23e-03	7.84e-03	4|247|11|3527	PF00063;PF00622;PF01576;PF02736
Group	GO:0008586	imaginal disc-derived wing vein morphogenesis	3	3.82	5.23e-03	7.84e-03	4|247|11|3527	PF00063;PF00431;PF01400;PF07645
Group	GO:0021872	forebrain generation of neurons	3	3.82	5.23e-03	7.84e-03	4|247|11|3527	PF00010;PF00046;PF00292;PF03299
Group	GO:0090090	negative regulation of canonical Wnt receptor signaling pathway	3	3.82	5.23e-03	7.84e-03	4|247|11|3527	PF00041;PF00110;PF01392;PF12444
Group	GO:0022412	cellular process involved in reproduction in multicellular organism	3	3.82	5.23e-03	7.84e-03	4|247|11|3527	PF00028;PF00100;PF00622;PF13895
Group	GO:0007044	cell-substrate junction assembly	3	3.82	5.23e-03	7.84e-03	4|247|11|3527	PF00053;PF00055;PF01391;PF07714
Group	GO:0001938	positive regulation of endothelial cell proliferation	3	3.82	5.23e-03	7.84e-03	4|247|11|3527	PF00019;PF00048;PF00074;PF00688
Group	GO:0030032	lamellipodium assembly	3	3.82	5.23e-03	7.84e-03	4|247|11|3527	PF00041;PF07714;PF13895;PF13927
Group	GO:0070304	positive regulation of stress-activated protein kinase signaling cascade	3	3.82	5.23e-03	7.84e-03	4|247|11|3527	PF00110;PF00615;PF05729;PF13516
Group	GO:0090192	regulation of glomerulus development	3	3.82	5.23e-03	7.84e-03	4|247|11|3527	PF00019;PF00386;PF00688;PF01391
Group	GO:0070374	positive regulation of ERK1 and ERK2 cascade	3	3.82	5.23e-03	7.84e-03	4|247|11|3527	PF00048;PF05729;PF07679;PF13895
Group	GO:0040036	regulation of fibroblast growth factor receptor signaling pathway	3	3.82	5.23e-03	7.84e-03	4|247|11|3527	PF00110;PF00320;PF07679;PF07714
Group	GO:0010103	stomatal complex morphogenesis	3	4.13	5.79e-03	8.44e-03	3|247|6|3527	PF00560;PF13516;PF13855
Group	GO:0060065	uterus development	3	4.13	5.79e-03	8.44e-03	3|247|6|3527	PF00046;PF00110;PF00320
Group	GO:0030220	platelet formation	3	4.13	5.79e-03	8.44e-03	3|247|6|3527	PF00063;PF01576;PF02736
Group	GO:0045806	negative regulation of endocytosis	3	4.13	5.79e-03	8.44e-03	3|247|6|3527	PF00386;PF01391;PF13895
Group	GO:0008355	olfactory learning	3	4.13	5.79e-03	8.44e-03	3|247|6|3527	PF00060;PF00497;PF01094
Group	GO:0032856	activation of Ras GTPase activity	3	4.13	5.79e-03	8.44e-03	3|247|6|3527	PF00041;PF01404;PF07714
Group	GO:0040019	positive regulation of embryonic development	3	4.13	5.79e-03	8.44e-03	3|247|6|3527	PF00046;PF00250;PF03529
Group	GO:0008347	glial cell migration	3	4.13	5.79e-03	8.44e-03	3|247|6|3527	PF00048;PF00167;PF01562
Group	GO:0032878	regulation of establishment or maintenance of cell polarity	3	4.13	5.79e-03	8.44e-03	3|247|6|3527	PF00049;PF00071;PF07714
Group	GO:2000794	regulation of epithelial cell proliferation involved in lung morphogenesis	3	4.13	5.79e-03	8.44e-03	3|247|6|3527	PF00110;PF07679;PF07714
Group	GO:0038007	netrin-activated signaling pathway	3	4.13	5.79e-03	8.44e-03	3|247|6|3527	PF00041;PF00090;PF07679
Group	GO:0003229	ventricular cardiac muscle tissue development	3	4.13	5.79e-03	8.44e-03	3|247|6|3527	PF00992;PF07679;PF07714
Group	GO:0048660	regulation of smooth muscle cell proliferation	3	3.46	6.50e-03	9.39e-03	5|247|18|3527	PF00010;PF00061;PF00074;PF00386;PF01391
Group	GO:2000242	negative regulation of reproductive process	3	3.46	6.50e-03	9.39e-03	5|247|18|3527	PF00046;PF00048;PF00079;PF00100;PF04505
Group	GO:0051302	regulation of cell division	3	3.46	6.50e-03	9.39e-03	5|247|18|3527	PF00010;PF00071;PF00167;PF07679;PF07714
Group	GO:0045766	positive regulation of angiogenesis	3	3.46	6.50e-03	9.39e-03	5|247|18|3527	PF00067;PF00071;PF00147;PF00167;PF00230
Group	GO:0046425	regulation of JAK-STAT cascade	3	3.46	6.50e-03	9.39e-03	5|247|18|3527	PF00010;PF00041;PF07714;PF11527;PF13927
Group	GO:0002260	lymphocyte homeostasis	3	3.46	6.50e-03	9.39e-03	5|247|18|3527	PF00019;PF00250;PF00613;PF00688;PF02192
Group	GO:0045824	negative regulation of innate immune response	4	8.93	1.11e-07	7.32e-07	6|247|6|3527	PF00041;PF00079;PF07679;PF07714;PF13895;PF13927
Group	GO:0048739	cardiac muscle fiber development	4	8.15	1.62e-06	8.29e-06	5|247|5|3527	PF00063;PF01576;PF02736;PF07686;PF13895
Group	GO:0023019	signal transduction involved in regulation of gene expression	4	7.33	9.17e-06	3.65e-05	5|247|6|3527	PF00010;PF00046;PF00167;PF00292;PF00320
Group	GO:0060317	cardiac epithelial to mesenchymal transition	4	7.33	9.17e-06	3.65e-05	5|247|6|3527	PF00010;PF00019;PF00110;PF00167;PF00688
Group	GO:0060911	cardiac cell fate commitment	4	7.29	2.35e-05	8.15e-05	4|247|4|3527	PF00046;PF00907;PF07679;PF13895
Group	GO:0017085	response to insecticide	4	7.29	2.35e-05	8.15e-05	4|247|4|3527	PF00003;PF02931;PF02932;PF07562
Group	GO:0072277	metanephric glomerular capillary formation	4	7.29	2.35e-05	8.15e-05	4|247|4|3527	PF00010;PF07679;PF07714;PF13895
Group	GO:0070723	response to cholesterol	4	7.29	2.35e-05	8.15e-05	4|247|4|3527	PF00019;PF00048;PF00067;PF00688
Group	GO:0035121	tail morphogenesis	4	7.29	2.35e-05	8.15e-05	4|247|4|3527	PF00110;PF00870;PF00907;PF02460
Group	GO:0030574	collagen catabolic process	4	7.29	2.35e-05	8.15e-05	4|247|4|3527	PF00045;PF00089;PF00413;PF01471
Group	GO:0007190	activation of adenylate cyclase activity	4	7.29	2.35e-05	8.15e-05	4|247|4|3527	PF00001;PF00089;PF00211;PF06327
Group	GO:0050766	positive regulation of phagocytosis	4	6.16	7.61e-05	2.34e-04	5|247|8|3527	PF00031;PF00059;PF02210;PF07686;PF13895
Group	GO:0042517	positive regulation of tyrosine phosphorylation of Stat3 protein	4	6.40	1.11e-04	3.24e-04	4|247|5|3527	PF00010;PF00041;PF11527;PF13927
Group	GO:0032720	negative regulation of tumor necrosis factor production	4	6.40	1.11e-04	3.24e-04	4|247|5|3527	PF00386;PF01391;PF02931;PF02932
Group	GO:0030917	midbrain-hindbrain boundary development	4	6.40	1.11e-04	3.24e-04	4|247|5|3527	PF00010;PF00046;PF00110;PF00167
Group	GO:0061036	positive regulation of cartilage development	4	6.40	1.11e-04	3.24e-04	4|247|5|3527	PF00010;PF00019;PF00688;PF12444
Group	GO:0032967	positive regulation of collagen biosynthetic process	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00001;PF00019;PF00688
Group	GO:0007339	binding of sperm to zona pellucida	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00084;PF00100;PF01562
Group	GO:0051891	positive regulation of cardioblast differentiation	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00019;PF00688;PF00907
Group	GO:0021879	forebrain neuron differentiation	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00046;PF00292;PF03299
Group	GO:0060501	positive regulation of epithelial cell proliferation involved in lung morphogenesis	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00110;PF07679;PF07714
Group	GO:0060527	prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00049;PF07679;PF07714
Group	GO:0051967	negative regulation of synaptic transmission, glutamatergic	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00060;PF01094;PF10613
Group	GO:0072205	metanephric collecting duct development	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00019;PF00110;PF00688
Group	GO:0032925	regulation of activin receptor signaling pathway	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00019;PF00688;PF03045
Group	GO:0035993	deltoid tuberosity development	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00010;PF00019;PF00688
Group	GO:0071688	striated muscle myosin thick filament assembly	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00063;PF01576;PF02736
Group	GO:0032808	lacrimal gland development	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00292;PF07679;PF07714
Group	GO:0071377	cellular response to glucagon stimulus	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00211;PF00631;PF06327
Group	GO:0072107	positive regulation of ureteric bud formation	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00019;PF00046;PF00320
Group	GO:0061144	alveolar secondary septum development	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF07679;PF07714;PF13895
Group	GO:0060385	axonogenesis involved in innervation	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF07679;PF07714;PF13895
Group	GO:0035990	tendon cell differentiation	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00010;PF00019;PF00688
Group	GO:0043951	negative regulation of cAMP-mediated signaling	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00001;PF00002;PF02793
Group	GO:0002687	positive regulation of leukocyte migration	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00001;PF00048;PF00100
Group	GO:0021762	substantia nigra development	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF07679;PF07714;PF13895
Group	GO:0045823	positive regulation of heart contraction	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00001;PF00019;PF00688
Group	GO:0061031	endodermal digestive tract morphogenesis	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00010;PF07679;PF07714
Group	GO:0032230	positive regulation of synaptic transmission, GABAergic	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00135;PF01094;PF10613
Group	GO:0060529	squamous basal epithelial stem cell differentiation involved in prostate gland acinus development	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00870;PF07679;PF07714
Group	GO:0031017	exocrine pancreas development	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00010;PF00041;PF00049
Group	GO:0043950	positive regulation of cAMP-mediated signaling	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00001;PF00002;PF02793
Group	GO:0032225	regulation of synaptic transmission, dopaminergic	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00001;PF00019;PF02931
Group	GO:0072375	medium-term memory	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00060;PF00497;PF01094
Group	GO:0090080	positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF07679;PF07714;PF13895
Group	GO:0048382	mesendoderm development	4	6.31	3.40e-04	7.45e-04	3|247|3|3527	PF00019;PF00167;PF00688
Group	GO:0030878	thyroid gland development	4	5.73	3.15e-04	7.45e-04	4|247|6|3527	PF00046;PF00167;PF00292;PF00907
Group	GO:0008343	adult feeding behavior	4	5.73	3.15e-04	7.45e-04	4|247|6|3527	PF00003;PF00159;PF02024;PF07562
Group	GO:0048662	negative regulation of smooth muscle cell proliferation	4	5.20	6.94e-04	1.38e-03	4|247|7|3527	PF00061;PF00074;PF00386;PF01391
Group	GO:0048485	sympathetic nervous system development	4	5.20	6.94e-04	1.38e-03	4|247|7|3527	PF00019;PF00320;PF00870;PF03299
Group	GO:2000352	negative regulation of endothelial cell apoptotic process	4	5.33	1.29e-03	2.30e-03	3|247|4|3527	PF00320;PF07714;PF13895
Group	GO:0006967	positive regulation of antifungal peptide biosynthetic process	4	5.33	1.29e-03	2.30e-03	3|247|4|3527	PF00560;PF13306;PF13855
Group	GO:0032757	positive regulation of interleukin-8 production	4	5.33	1.29e-03	2.30e-03	3|247|4|3527	PF00386;PF01391;PF13855
Group	GO:0016266	O-glycan processing	4	5.33	1.29e-03	2.30e-03	3|247|4|3527	PF00094;PF01390;PF01762
Group	GO:0007340	acrosome reaction	4	5.33	1.29e-03	2.30e-03	3|247|4|3527	PF00089;PF02931;PF02932
Group	GO:0051770	positive regulation of nitric-oxide synthase biosynthetic process	4	5.33	1.29e-03	2.30e-03	3|247|4|3527	PF07714;PF13516;PF13855
Group	GO:0060601	lateral sprouting from an epithelium	4	5.33	1.29e-03	2.30e-03	3|247|4|3527	PF00870;PF07679;PF07714
Group	GO:0007194	negative regulation of adenylate cyclase activity	4	5.33	1.29e-03	2.30e-03	3|247|4|3527	PF00001;PF00003;PF01094
Group	GO:0060081	membrane hyperpolarization	4	5.33	1.29e-03	2.30e-03	3|247|4|3527	PF00135;PF02931;PF10613
Group	GO:0034122	negative regulation of toll-like receptor signaling pathway	4	5.33	1.29e-03	2.30e-03	3|247|4|3527	PF00041;PF07679;PF07714
Group	GO:0006968	cellular defense response	4	5.33	1.29e-03	2.30e-03	3|247|4|3527	PF00001;PF00059;PF13895
Group	GO:0061029	eyelid development in camera-type eye	4	5.33	1.29e-03	2.30e-03	3|247|4|3527	PF00019;PF00688;PF03299
Group	GO:0060395	SMAD protein signal transduction	4	5.33	1.29e-03	2.30e-03	3|247|4|3527	PF00019;PF00320;PF00688
Group	GO:0045776	negative regulation of blood pressure	4	5.33	1.29e-03	2.30e-03	3|247|4|3527	PF00001;PF00386;PF01391
Group	GO:0071205	protein localization to juxtaparanode region of axon	4	5.33	1.29e-03	2.30e-03	3|247|4|3527	PF00041;PF07679;PF13895
Group	GO:0070373	negative regulation of ERK1 and ERK2 cascade	4	5.33	1.29e-03	2.30e-03	3|247|4|3527	PF00049;PF00386;PF01391
Group	GO:0050916	sensory perception of sweet taste	4	5.33	1.29e-03	2.30e-03	3|247|4|3527	PF00003;PF01094;PF07562
Group	GO:0042573	retinoic acid metabolic process	4	4.65	3.05e-03	4.90e-03	3|247|5|3527	PF00061;PF00067;PF00201
Group	GO:0048484	enteric nervous system development	4	4.65	3.05e-03	4.90e-03	3|247|5|3527	PF00019;PF00046;PF12444
Group	GO:0006940	regulation of smooth muscle contraction	4	4.65	3.05e-03	4.90e-03	3|247|5|3527	PF00001;PF02931;PF02932
Group	GO:0045648	positive regulation of erythrocyte differentiation	4	4.65	3.05e-03	4.90e-03	3|247|5|3527	PF00010;PF00019;PF00688
Group	GO:2000611	positive regulation of thyroid hormone generation	4	4.65	3.05e-03	4.90e-03	3|247|5|3527	PF00089;PF00292;PF00320
Group	GO:0061298	retina vasculature development in camera-type eye	4	4.65	3.05e-03	4.90e-03	3|247|5|3527	PF01534;PF07679;PF13895
Group	GO:0003209	cardiac atrium morphogenesis	4	4.65	3.05e-03	4.90e-03	3|247|5|3527	PF00046;PF00110;PF07645
Group	GO:0008156	negative regulation of DNA replication	4	4.13	5.79e-03	8.44e-03	3|247|6|3527	PF00019;PF00688;PF00870
Group	GO:0045721	negative regulation of gluconeogenesis	4	4.13	5.79e-03	8.44e-03	3|247|6|3527	PF00061;PF00386;PF01391
Group	GO:0030501	positive regulation of bone mineralization	4	4.13	5.79e-03	8.44e-03	3|247|6|3527	PF00019;PF00688;PF03299
Group	GO:0043392	negative regulation of DNA binding	4	4.13	5.79e-03	8.44e-03	3|247|6|3527	PF00010;PF00046;PF01534
